Nanobodies targeting CD28 and their applications

By developing nanobodies targeting CD28, the problems of drug resistance to CD3 bispecific antibodies and the safety of conventional CD28 antibodies have been solved, achieving highly active and safe T-cell activation, which is suitable for the treatment of diseases such as hematological malignancies.

CN123106900APending Publication Date: 2026-11-17GUANGDONG FAPON BIOPHARMA INC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202610653417.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2025-05-15
Filing Date
2026-05-12
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing CD3 bispecific antibodies have drug resistance issues in the treatment of hematological malignancies, and conventional CD28 antibodies pose safety risks as super agonists. Positive nanobodies have weak activity and insufficient dependence.

Method used

A nanobody targeting CD28 was developed, which is first signal dependent, does not activate T cells in the absence of CD3 stimulation, has strong binding activity and high safety, and has specific amino acid sequence identity, including heavy chain variable regions and HCDRs.

Benefits of technology

This approach achieves improved safety and dependence of T cell activation, reduced risk of T cell apoptosis, and enhanced therapeutic efficacy while ensuring antibody activity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

This application discloses an antibody or its antigen-binding fragment, which includes a heavy chain variable region. The antibody or its antigen-binding fragment of this application exhibits high CD28 binding activity and safety. In particular, the above-mentioned antibody or its antigen-binding fragment, while ensuring antibody activity, also possesses first-signal dependence (it does not activate T cells in the absence of CD3 stimulation), thus demonstrating excellent safety.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Priority information This application claims priority and benefit to patent application 202510631564.3, filed with the China National Intellectual Property Administration on May 15, 2025, the entire contents of which are incorporated herein by reference. Technical Field

[0002] This application belongs to the field of biomedical technology, specifically involving nanobodies targeting CD28 and their applications. Background Technology

[0003] CD28 is a costimulatory molecule expressed on the surface of T cells, playing a crucial role in T cell activation, proliferation, and differentiation. The structure of CD28 comprises an extracellular region, a transmembrane region, and an intracellular region. The extracellular region is responsible for ligand binding, primarily with B7 family molecules found on the surface of antigen-presenting cells (APCs), such as CD80 (B7-1) and CD86 (B7-2).

[0004] When the T cell receptor (TCR) recognizes an antigenic peptide presented by MHC molecules, the interaction between CD28 and B7 molecules provides a crucial co-stimulatory signal. This signal is essential for activating a range of signaling pathways within T cells (such as PI3K / Akt and MAPK) and can promote the production of cytokines (such as IL-2), enhancing T cell survival and proliferation. CD28 is particularly important for the activation of naive T cells in the immune response. The lack of CD28 co-stimulatory signaling can lead to T cell anergy or apoptosis. Therefore, developing a novel anti-CD28 antibody is of great importance. Summary of the Invention

[0005] This application aims to at least partially address one of the technical problems existing in the prior art. To this end, this application provides a nanobody targeting CD28.

[0006] This application is based on the inventor's following discoveries: Currently available bispecific antibodies targeting CD3 have demonstrated significant efficacy in treating hematological malignancies, but drug resistance is a common problem. This is because CD3 antibodies only provide the first signal for T cell activation; overstimulation of this first signal can easily lead to T cell apoptosis and subsequent drug resistance. CD28, as a second signaling molecule, can help T cells activate more effectively, maintain T cell activity, and reduce T cell apoptosis. Most discovered CD28 antibodies are conventional antibodies. In contrast, nanobodies have advantages such as small molecular weight, good stability, and high yield. However, the conventional positive CD28 antibody used is a super agonist, highly active, and can significantly activate T cells independently of the first signal (CD3 activation), raising safety concerns. Another positive nanobody exhibits first signal dependence (it does not activate T cells without CD3 stimulation), offering relatively better safety, but with weaker activity. However, CD28 nanobodies are currently very rare.

[0007] Based on this, this application develops a CD28 nanobody that, while ensuring antibody activity, also exhibits first signal dependence (it does not activate T cells in the absence of CD3 stimulation) and has relatively better safety.

[0008] Therefore, in a first aspect of this application, an antibody or antigen-binding fragment thereof is provided. According to embodiments of this application, the antibody or antigen-binding fragment thereof includes a heavy chain variable region; the heavy chain variable region has an amino acid sequence having at least 80%, 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, or 100% identity as shown in any one of SEQ ID NO: 1-15 or SEQ ID NO: 150-153. The antibody or antigen-binding fragment thereof of this application has high CD28 binding activity and safety.

[0009] In a second aspect of this application, an antibody or antigen-binding fragment thereof is provided. According to embodiments of this application, the antibody or antigen-binding fragment thereof includes HCDRs; the HCDRs are HCDRs consistent with the HCDRs of the heavy chain variable region defined by the antibody or antigen-binding fragment thereof described in the first aspect. The antibody or antigen-binding fragment thereof of this application has high CD28 binding activity and safety.

[0010] In a third aspect, this application provides an antibody or an antigen-binding fragment thereof. According to embodiments of this application, the antibody or antigen-binding fragment thereof includes HCDR1, HCDR2, and HCDR3; wherein: HCDR1: NYVMG; HCDR2: TITWX 46 X47 GTYYADSVKG, X 46 For N or Q, X 47 It can be G or A; HCDR3: SPLISMDASDFNS; or HCDR1: X1X2AYTMX3, where X1 is empty or L, X2 is empty or F, and X3 is A or G; HCDR2:SLWWNX 48 X 49 ATYYADSVKG, X 48 For D or E, X 49 It can be G or A; HCDR3: KAGX4YX5YNRAEAX6X 45 S, X4 is S, Y, or W, X5 is D or N, X6 is F or Y, X 45 For T or R; or HCDR1: VAGX7D, where X7 is C or S; HCDR2: RVMPDX8VRTYAESVKG, where X8 is G or A; HCDR3: HFWARDY.

[0011] The antibody or its antigen-binding fragment of this application has high CD28 binding activity and safety.

[0012] On the other hand, this application proposes an antibody or an antigen-binding fragment thereof. According to embodiments of this application, the antibody or antigen-binding fragment thereof includes HCDR1, HCDR2, and HCDR3; wherein: HCDR1: NYVMG; HCDR2: TITWX 46 X 47 GTYYADSVKG, X 46 For N or Q, X 47 It can be G or A; HCDR3: SPLISMDASDFNS; or HCDR1: X1X2AYTMX3, where X1 is empty or L, X2 is empty or F, and X3 is A or G; HCDR2:SLWWNX 48 X 49 ATYYADSVKG, X 48 For D or E, X 49 It can be G or A; HCDR3: KAGX4YX5YNRAEAX6TS, where X4 is S, Y, or W, X5 is D or N, and X6 is F or Y; or HCDR1: VAGX7D, where X7 is C or S; HCDR2: RVMPDX8VRTYAESVKG, where X8 is G or A; HCDR3: HFWARDY.

[0013] The antibody or its antigen-binding fragment of this application has high CD28 binding activity and safety.

[0014] In a fourth aspect, this application provides a biomaterial comprising any one of the following (i) to (vii): (i) A nucleic acid molecule that encodes an antibody or an antigen-binding fragment thereof as described in any one of the first to third aspects; (ii) A vector comprising the nucleic acid molecule described in (i); (iii) A cell or host comprising: (i) the nucleic acid molecule or (ii) the vector; or expressing an antibody or an antigen-binding fragment thereof as described in any one of the first to third aspects; (iv) A conjugate, characterized in that it comprises: an antibody or an antigen-binding fragment thereof as described in any one of the first to third aspects, and a conjugate portion therewith; According to embodiments of this application, the coupling portion includes a selection from purification tags or labels; According to embodiments of this application, the purification label or marker includes at least one selected from colloidal gold, radioactive labeling, luminescent substances, colored substances, enzymes, biotin / avidin, and spin labeling. According to embodiments of this application, the purification label or marker includes at least one selected from fluorescent markers, chromophore markers, and electron-dense markers; According to embodiments of this application, the purification label or marker includes one or more selected from radioactive isotopes, fluorophores, rhodamine and its derivatives, luciferase, luciferin, horseradish peroxidase, alkaline phosphatase, β-galactosidase, glucosylamylase, lysozyme, carbohydrate oxidase, glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase. According to embodiments of this application, the coupling portion includes at least one selected from magnetic microspheres, plastic microspheres, plastic microparticles, microporous plates, glass, capillaries, nylon, and nitrocellulose membranes; (v) A reagent or kit, characterized in that it comprises: an antibody or antigen-binding fragment thereof as described in any one of the first to third aspects, or a conjugate as described in (iv).

[0015] In a fifth aspect of this application, a pharmaceutical composition is provided. According to embodiments of this application, the pharmaceutical composition comprises an antibody or antigen-binding fragment thereof as described in the first, second, or third aspect, and the biological material as described in the fourth aspect.

[0016] In a sixth aspect of this application, the use of the antibody or antigen-binding fragment thereof described in the first, second or third aspect, the biological material described in the fourth aspect, or the pharmaceutical composition described in the ninth aspect in the preparation of a medicament for the treatment, prevention or relief of diseases, symptoms or conditions associated with tumors, inflammation, autoimmune diseases, infections, or immune rejection of organ transplants is provided.

[0017] In a seventh aspect of this application, the use of the antibody or antigen-binding fragment thereof described in the first, second or third aspect, and the biological material described in the fourth aspect in the preparation of a product for detecting CD28 or detecting cells expressing CD28.

[0018] In an eighth aspect of this application, a method for treating, preventing, or alleviating a disease, symptom, or condition is provided. According to embodiments of this application, the method includes administering to a subject a pharmaceutically acceptable dose of an antibody or antigen-binding fragment thereof described in the first, second, or third aspect, a biological material described in the fourth aspect, or a pharmaceutical composition described in the ninth aspect.

[0019] In a ninth aspect of this application, a method for detecting CD28 is provided. According to an embodiment of this application, the method includes: contacting the sample to be tested with an antibody or antigen-binding fragment thereof described in the first, second, or third aspect, and the biological material described in the fourth aspect, to form an immune complex.

[0020] Additional aspects and advantages of this application will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of this application. Attached Figure Description

[0021] The above and / or additional aspects and advantages of this application will become apparent and readily understood from the description of the embodiments taken in conjunction with the following drawings, in which: Figure 1 The results show the binding activity of each CD28 candidate nanobody and positive control antibody in Example 3 of this application with 293-hCD28 cells; Figure 2 The results of primary T cell activation activity (including CD3 antibody) of each CD28 candidate nanobody and positive control antibody in Example 4 of this application; Figure 3The results of primary T cell activation activity of each CD28 candidate nanobody and positive control antibody in Example 5 of this application (excluding CD3 antibody); Figure 4 The results show the epitope competition activity of each CD28 candidate nanobody in Example 6 of this application; Figure 5 shows the binding activity results of the humanized CD28 candidate nanobodies and 293-hCD28 cells in Example 8 of this application; Figure 6 shows the primary T cell activation activity results (including CD3 antibody) of each CD28 candidate nanobody and positive control antibody in Example 9 of this application; Figure 7 The results show the binding activity of the PTM-modified antibody in Example 11 of this application on 293-hCD28 cells; Figure 8 The results show the primary T cell activation activity of the PTM-modified antibody in Example 12 of this application. Detailed Implementation

[0022] The embodiments of this application are described in detail below. The embodiments described below are exemplary and are only used to explain this application, and should not be construed as limiting this application.

[0023] This application details Definitions and General Terms It should be noted that the terms "first" and "second" are used for descriptive purposes only and should not be construed as indicating or implying relative importance or implicitly specifying the number of technical features indicated. Therefore, a feature defined as "first" or "second" may explicitly or implicitly include one or more of that feature. Furthermore, in the description of this application, unless otherwise stated, "multiple" means two or more.

[0024] The endpoints and any values ​​of the ranges disclosed herein are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of the various ranges, the endpoint values ​​of the various ranges and individual point values, and individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed herein.

[0025] To facilitate understanding of this application, certain technical and scientific terms are specifically defined below. Unless otherwise expressly defined elsewhere in this document, all other technical and scientific terms used herein have the meanings commonly understood by one of ordinary skill in the art to which this application pertains. Abbreviations for amino acid residues are standard 3-letter and / or 1-letter codes used in the art to refer to one of the 20 commonly used L-amino acids (i.e., amino acids with a levorotatory conformation).

[0026] In this document, the terms “comprising” or “including” are open-ended expressions, meaning that they include the contents specified in this application but do not exclude other contents.

[0027] In this document, the terms “optional,” “optional,” “alternatively,” “optional,” or “optional” generally refer to an event or condition that may or may not occur as described below, and the description includes both cases in which the event or condition occurs and cases in which the event or condition does not occur.

[0028] The term "amino acid" refers to naturally occurring amino acids and synthetic amino acids, as well as amino acid analogs and amino acid mimics that function in a similar manner to naturally occurring amino acids. Naturally occurring amino acids include those encoded by the genetic code and their modified forms, such as hydroxyproline, γ-carboxyglutamic acid, and O-phosphoserine. Common naturally occurring amino acids include: alanine (Ala; A), arginine (Arg; R), asparagine (Asn; N), aspartic acid (Asp; D), cysteine ​​(Cys; C); glutamic acid (Glu; E), glutamine (Gln; Q), glycine (Gly; G); histidine (His; H), isoleucine (Ile; I), leucine (Leu; L), lysine (Lys; K), methionine (Met; M), phenylalanine (Phe; F), proline (Pro; P), serine (Ser; S), threonine (Thr; T), tryptophan (Trp; W), tyrosine (Tyr; Y), and valine (Val; V). Amino acid analogs are compounds that have the same basic chemical structure as naturally occurring amino acids (i.e., the α-carbon bound to hydrogen, carboxyl, amino, and R groups), such as homoserine, ortholeucine, methionine sulfoxide, and methionine methylsulfonium. Amino acid analogs typically have modified R groups (e.g., ortholeucine) or modified peptide backbones, but retain the same basic chemical structure as naturally occurring amino acids. Amino acid mimics are chemical compounds that have a structure different from the general chemical structure of amino acids, but function in a similar manner to naturally occurring amino acids.

[0029] In this article, the term “antibody” is used in the broadest sense, which can include full-length monoclonal antibodies, multispecific antibodies, chimeric antibodies, or functional fragments, with no restrictions on their specific structure, as long as they exhibit the desired antigen-binding activity.

[0030] In this article, the terms “full-length antibody”, “full-length monoclonal antibody” or “full-length monoclonal antibody” refer to antibodies composed of at least two identical light chains and at least two identical heavy chains linked by interchain disulfide bonds, such as immunoglobulin G (IgG), immunoglobulin A (IgA), immunoglobulin M (IgM), immunoglobulin D (IgD), or immunoglobulin E (IgE).

[0031] In this document, the term "functional fragment" refers to a fragment containing part or all of an antibody that lacks at least some of the amino acids present in the full-length chain but still possesses the performance activity of specifically binding to an antigen. For example, the fragment may contain part or all of the antibody's CDR. Such fragments are biologically active because they bind to the antigen and can compete with other antigen-binding molecules (including intact antibodies) for binding to a given epitope. Such fragments can be generated using recombinant nucleic acid technology or through enzymatic or chemical cleavage of antigen-binding molecules (including intact antibodies).

[0032] In this article, the term "nanobody" generally refers to the heavy chain variable region (VHH) portion of a naturally occurring heavy chain antibody that lacks a light chain. Heavy chain antibodies are commonly found in alpacas and consist of a heavy chain variable region (VHH) and conventional CH2 and CH3 regions. They bind specifically to antigens through the heavy chain variable region (VHH), and the heavy chain variable region (VHH) alone can exert an antigen-specific binding effect.

[0033] In this paper, the terms “identity,” “homology,” or “similarity” are used to describe the percentage of identical amino acids or nucleotides between two amino acid sequences or nucleic acid sequences relative to a reference sequence, determined by conventional methods, for example, see Ausubel et al., eds. (1995), Current Protocols in Molecular Biology, Chapter 19 (Greene Publishing and Wiley-Interscience, New York); and the ALIGN procedure (Dayhoff (1978), Atlas of Protein Sequence and Structure 5: Suppl. 3 (National Biomedical Research Institute)). Foundation, Washington, DC). Numerous algorithms exist for aligning sequences and determining sequence identity, including: the homology alignment algorithm of Needleman et al. (1970) J. Mol. Biol. 48: 443; the local homology algorithm of Smith et al. (1981) Adv. Appl. Math. 2: 482; the similarity search method of Pearson et al. (1988) Proc. Natl. Acad. Sci. 85: 2444; the Smith-Waterman algorithm (Meth. Mol. Biol. 70: 173-187 (1997); and the BLASTP, BLASTN, and BLASTX algorithms (see Altschul et al. (1990) J. Mol. Biol. 215: 403-410). Computer programs utilizing these algorithms are also available, including but not limited to: ALIGN or Megalign (DNASTAR) software, or WU-BLAST-2 (Altschul...). See, Meth.Enzym., 266:460-480 (1996); or GAP, BESTFIT, BLAST Altschul, etc., above, FASTA, and TFASTA, available in Genetics Computing Group (GCG) package, version 8, Madison, Wisconsin, USA; and CLUSTAL in the PC / Gene program provided by Intelligenetics, Mountain View, California.

[0034] Without substantially affecting antibody activity (retaining at least 90% of the activity), those skilled in the art can substitute, add, and / or delete one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more) amino acids in the sequence of this application to obtain variants of the antibody sequence. These are all considered to be included within the scope of protection of this application. For example, amino acids with similar properties can be substituted in the variable region. The variant sequences described in this application can have at least 90%, 95%, 96%, 97%, 98%, or 99% identity (or homology) with the reference sequence. The sequence identity described in this application can be measured using sequence analysis software, such as the computer program BLAST using default parameters, especially BLASTP or TBLASTN. The amino acid sequences mentioned in this application are shown in N-terminus to C-terminus format.

[0035] It should be noted that, in the claims and specification herein, the variant of the antibody sequence is obtained by adding and / or deleting one or more amino acids based on the heavy chain or the variable region of the heavy chain. The position or number of the mutation site defined in the specification and claims of this application also needs to be adjusted according to the number and position of the added and / or deleted amino acids.

[0036] In this paper, the term "at least 60% homology" refers to a homology of at least 60% with each reference sequence, which may be 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9%. For example, at least 70% (which may be 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9% homology), at least 75% (which may be 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9% homology), at least 80% (which may be 80%, 81%) %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9% homology), at least 85% (can be 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9% homology), at least 90% (can be 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9% homology), at least 95% (can be 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9% homology).

[0037] In this paper, the term “variant” or “mutant” can refer to any naturally occurring or engineered molecule that contains one or more nucleotide or amino acid mutations.

[0038] In this document, the term "vector" generally refers to a nucleic acid molecule capable of self-replication within a suitable host, transferring the inserted nucleic acid molecule into and / or between cells or hosts. The vector may include vectors primarily for inserting DNA or RNA into cells, vectors primarily for replicating DNA or RNA, and expression vectors primarily for transcription and / or translation of DNA or RNA. The vector also includes vectors having multiple of the aforementioned functions. The vector may be a polynucleotide capable of being transcribed and translated into a polypeptide when introduced into a suitable cell or host. Typically, by culturing a suitable cell or host containing the vector, the vector can produce the desired expression product.

[0039] In this document, the term "cell" generally refers to a cell whose genetic material has been modified or recombined using genetic engineering or cell fusion techniques to obtain a unique trait with stable inheritance. The term "host cell" refers to a prokaryotic or eukaryotic cell into which a recombinant vector can be introduced. The terms "transformed" or "transfected" as used herein refer to the introduction of nucleic acids (e.g., vectors) into cells using various techniques known in the art. Suitable host cells can be transformed or transfected with the DNA sequence of this application and can be used for the expression and / or secretion of target proteins. Examples of suitable host cells that can be used in this application include immortalized hybridoma cells, NS / 0 myeloma cells, 293 cells, Chinese hamster ovary (CHO) cells, HeLa cells, Cap cells (cells derived from human amniotic fluid), and CoS cells.

[0040] In this document, the term "pharmaceutical composition" generally refers to a composition in unit dose form and can be prepared by any method well known in the pharmaceutical industry. All methods involve the step of combining the active ingredient with a carrier constituting one or more adjunct components.

[0041] In this article, the term "pharmaceuticalally acceptable" refers to a substance that is suitable for use in humans and / or mammals without excessive adverse side effects (such as toxicity, irritation, and allergic reactions), i.e., a substance with a reasonable benefit / risk ratio.

[0042] In this document, the term "pharmaceuticalally acceptable excipient" may include any solvent, stabilizer, diluent, or other liquid excipient, etc., suitable for a specific target dosage form. The use of any conventional excipients is also within the scope of consideration for this application, except for any range of incompatibility between the excipient and the antibody or its antigen-binding fragment of this application, such as any adverse biological effects or harmful interactions with any other component of the pharmaceutically acceptable composition.

[0043] In this document, the term "administration" refers to the introduction of a predetermined amount of a substance into a patient in a suitable manner. The antibody or its antigen-binding fragment, or the pharmaceutical composition of this application, can be administered via any common route, as long as it can reach the intended tissue. Various routes of administration are foreseeable, including peritoneal, intravenous, intramuscular, subcutaneous, etc., but this application is not limited to these exemplified routes of administration. Preferably, the antibody or its antigen-binding fragment, or the pharmaceutical composition of this application is administered via intravenous or subcutaneous injection.

[0044] In this document, the term "treatment" refers to the use of drugs to achieve desired pharmacological and / or physiological effects. These effects may be preventative in terms of complete or partial prevention of disease or its symptoms, and / or therapeutic in terms of partial or complete cure of disease and / or adverse effects caused by disease. As used herein, "treatment" encompasses diseases in mammals, particularly humans, including: (a) prevention of disease or the onset of disease in susceptible individuals who have not yet been diagnosed with the disease; (b) inhibition of disease, such as blocking disease progression; or (c) alleviation of disease, such as reducing disease-related symptoms. As used herein, "treatment" encompasses any medication that administers an antibody or its antigen-binding fragment or a pharmaceutical composition to an individual to treat, cure, alleviate, improve, reduce, or inhibit the individual's disease, including but not limited to administering a drug containing an antibody or its antigen-binding fragment described herein to an individual in need.

[0045] As used herein, the term “effective amount” or “effective dose” means an amount that is functional or active in humans and / or animals and is acceptable to humans and / or animals.

[0046] In this article, tumors, inflammation, autoimmune diseases, infections, and immune rejection caused by organ transplantation include, but are not limited to, one or more of the following: gastric cancer, esophageal cancer, head and neck cancer, bladder cancer, cervical cancer, sarcoma, cell tumor, lung cancer, colon cancer, ovarian cancer, kidney cancer, colorectal cancer, pancreatic cancer, liver cancer, melanoma, breast cancer, myeloma, squamous cell carcinoma, urogenital cancer, rectal cancer, sarcoma, testicular cancer, cervical cancer, mast cell tumor, hemangioma, eye cancer, laryngeal cancer, oral cancer, mesothelioma, skin cancer, rectal cancer, uterine cancer, brain cancer, and glioma.

[0047] In this article, tumors include, but are not limited to, hematologic malignancies. Exemplary hematologic malignancies include, but are not limited to, one or more of the following: chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), B-cell malignancies, lymphomas (Hodgkin's lymphoma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, myeloma), and myeloproliferative disorders.

[0048] This application provides a detailed description of CD28-targeting nanobodies and their applications. This application discloses an anti-CD28 antibody or its antigen-binding fragment, nucleic acid, vector, cell or host, conjugate, reagent or kit, pharmaceutical composition, and their uses and methods, which will be described in detail below.

[0049] Antibody or its antigen-binding fragment In a first aspect of this application, an antibody or antigen-binding fragment thereof is provided. According to an embodiment of this application, the antibody or antigen-binding fragment thereof includes a heavy chain variable region; the heavy chain variable region has an amino acid sequence having at least 80%, 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, or 100% identity as shown in any one of SEQ ID NO:1-15 or SEQ ID NO:150-153.

[0050] FR2-19: DVQLQESGGGLVQAGGSLRLSCATSGRTFVNYVMGWFRQAPGKEREFVATITWNGGTYYADSVKGRFTISDDRPKNTVYLQMNSLKPEDTGVYYCAASPLISMDASDFNSWGQGTQVTVSS(SEQ ID NO:1); FR2-96: DVQLQESGGGLVQAGGSLRLLCAASGSTFFAYTMAWFRQAPGKEREFVASLWWNDGATYYADSVKGRFTVSRDNAENTVFLQMNSLKAEDTAVYYCGAKAGSYDYNRAEAFTSWGRGTQVTVS(SEQ ID NO:2); S3-20: DVQLVESGGGLVQAGDSLRLSCAASGGTLFAYTMGWFRQAPGKEREFVGSLWWNDGATYYADSVKGRFTISRGNAENTVFLQMNSLKAEDTAVYYCAAKAGYYDYNRAEAFRSWGQGTQVTVS (SEQ ID NO:3); S3-62: DVQLQESGGGLVQAGGSLRLLCAASISGRTLFAYTMGWFRQAPGKEREFVASLWWNDGATYYADSVKGRFTISRDNAENTVFLEMNNLKAEDTAVYYCAAKAGWYNYNRAEAYTSWGQGTQVT (SEQ ID NO:4); S3-44: QVQLVESGGGLVQPGGSLRLSCAASGSIFSVAGCDWYREAPGKQRDWVARVMPDGVRTYAESVKGRFTISTDNTFSTVYLEMNSLKPEDTAHYYCKTHFWARDYWGQGTQVTVLR(SEQ ID NO:5); R4570: QVQLVESGGGVVQPGGSLRLSCATSGRTFVNYVMGWFRQAPGKEREFVATITWNGGTYYADSVKGRFTISDDRSKNTVYLQMNSLRAEDTAVYYCAASPLISMDASDFNSWGQGTLVTVSS (SEQ ID NO:9); R4572: QVQLVESGGGVVQPGGSLRLSCATSGRTFVNYVMGWFRQAPGKGLEFVATITWNGGTYYADSVKGRFTISDDRSKNTVYLQMNSLRAEDTAVYYCAASPLISMDASDFNSWGQGTLVTVSS (SEQ ID NO:6); R4585: QVQLVESGGGVVQPGGSLRLSCAASISGRTLFAYTMGWFRQAPGKGLEFVASLWWNDGATYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAAKAGWYNYNRAEAYTSWGQGTLVTVSS (SEQ ID NO:10); R4586: QVQLVESGGGVVQPGGSLRLSCAASISGRTLFAYTMGWFRQAPGKEREFVASLWWNDGATYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAAKAGWYNYNRAEAYTSWGQGTLVTVSS (SEQ ID NO:11); R4587: QVQLVESGGGVVQPGGSLRLSCAASISGRTLFAYTMGWFRQAPGKEREFVASLWWNDGATYYADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCAAKAGWYNYNRAEAYTSWGQGTLVTVSS (SEQ ID NO:12); R4588: QVQLVESGGGVVQPGGSLRLSCAASISGRTLFAYTMGWFRQAPGKGLEFVASLWWNDGATYYADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCAAKAGWYNYNRAEAYTSWGQGTLVTVSS (SEQ ID NO:13); R4589: QVQLVESGGGVVQPGGSLRLSCAASISGRTLFAYTMGWFRQAPGKEREFVASLWWNDGATYYADSVKGRFTISRDNSKNTVYLEMNSLRAEDTAVYYCAAKAGWYNYNRAEAYTSWGQGTLVTVSS (SEQ ID NO:7); R4697: QVQLVESGGGVVQPGGSLRLSCAASGSIFSVAGSDWYREAPGKQREWVARVMPDAVRTYAESVKGRFTISTDNSFSTVYLEMNSLRAEDTAVYYCKTHFWARDYWGQGTLVTVSS (SEQ ID NO:8); R4698: QVQLVESGGGVVQPGGSLRLSCAASGSIFSVAGSDWYREAPGKQREWVARVMPDAVRTYAESVKGRFTISTDNSFSTVYLEMNSLKAEDTAVYYCKTHFWARDYWGQGTLVTVSS (SEQ ID NO:14); R4699: QVQLVESGGGVVQPGGSLRLSCAASGSIFSVAGSDWYREAPGKQREWVARVMPDAVRTYAESVKGRFTISTDNSFSTVYLEMNSLKAEDTAHYYCKTHFWARDYWGQGTLVTVSS (SEQ ID NO:15); R4977: QVQLVESGGGVVQPGGSLRLSCATSGRTFVNYVMGWFRQAPGKGLEFVATITWQGGTYYADSVKGRFTISDRSKNTVYLQMNSLRAEDTAVYYCAASPLISMDASDFNSWGQGTLVTVSS (SEQ ID NO:150); R4978: QVQLVESGGGVVQPGGSLRLSCATSGRTFVNYVMGWFRQAPGKGLEFVATITWNAGTYYADSVKGRFTISDRSKNTVYLQMNSLRAEDTAVYYCAASPLISMDASDFNSWGQGTLVTVSS (SEQ ID NO:151); R4979: QVQLVESGGGVVQPGGSLRLSCAASISGRTLFAYTMGWFRQAPGKEREFVASLWWNEGATYYADSVKGRFTISRDNSKNTVYLEMNSLRAEDTAVYYCAAKAGWYNYNRAEAYTSWGQGTLVTVSS (SEQ ID NO:152); R4980: QVQLVESGGGVVQPGGSLRLSCAASISGRTLFAYTMGWFRQAPGKEREFVASLWWNDAATYYADSVKGRFTISRDNSKNTVYLEMNSLRAEDTAVYYCAAKAGWYNYNRAEAYTSWGQGTLVTVSS (SEQ ID NO: 153).

[0051] In a second aspect of this application, an antibody or antigen-binding fragment thereof is provided. According to an embodiment of this application, the antibody or antigen-binding fragment thereof includes HCDRs; the HCDRs are HCDRs consistent with the HCDRs of the heavy chain variable region defined by the antibody or antigen-binding fragment thereof described in the first aspect.

[0052] In this document, the terms "complementarity-determining region," "CDR," or "CDRs" refer to highly variable regions of the heavy chain of an immunoglobulin, specifically regions containing one or more of the major amino acid residues responsible for binding affinity to recognized antigens or epitopes. In specific embodiments of this disclosure, CDRs refer to highly variable regions of the heavy chain of the antibody.

[0053] In this document, heavy chain complementarity-determining regions (heavy chain variable regions, CDRs) are referred to as “HCDRs” or “HCDRs”, including HCDR1, HCDR2, and HCDR3. Commonly used CDR numbering schemes in the art include: Kabat numbering, Chothia numbering, IMGT numbering, Chothia-Martin numbering, and AHoLesk numbering. CDR definition schemes include: Kabat definition, Chothia definition, IMGT definition, Contact definition, and AbM definition. As described herein, “Kabat numbering” and “Kabat definition” refer to the numbering and definition system described in Kabat et al., USDept. of Health and Human Services, “Sequence of Proteins of Immunological Interest” (1983). For “Chothia definition”, see Chothia et al., J Mol Biol 196: 901-917 (1987). Exemplary defined CDRs are listed in Table A1 below. Given the amino acid sequence of the variable region of an antibody, those skilled in the art can routinely determine which residues contain a specific CDR.

[0054] Table A1: CDR Definition 1

[0055] 1 The numbers for all CDRs defined in Table A1 are based on the Kabat numbering system (see below).

[0056] 2 As shown in Table A1, “AbM” with a lowercase “b” refers to the CDR defined by the “AbM” antibody modeling software of Oxford Molecular.

[0057] Kabat et al. also defined a numbering system applicable to the variable region sequence of any antibody. Those skilled in the art can readily map this Kabat numbering system to any variable region sequence without relying on any experimental data outside the sequence itself. As used herein, “Kabat numbering” refers to the numbering system described by Kabat et al., USD ept. of Health and Human Services, “Sequence of Proteins of Immunological Interest” (1983).

[0058] According to embodiments of this application, the HCDRs are defined by the Kabat, Chothia, AbM, Contact, or IMGT system.

[0059] In an optional embodiment of this application, HCDR1, HCDR2 and HCDR3 are defined by the same system (any one of Kabat, Chothia, AbM, Contact, or IMGT systems).

[0060] In a third aspect, this application provides an antibody or an antigen-binding fragment thereof. According to embodiments of this application, the antibody or antigen-binding fragment thereof includes HCDR1, HCDR2, and HCDR3; wherein: HCDR1: NYVMG; HCDR2: TITWX 46 X 47 GTYYADSVKG, X 46 For N or Q, X 47 It can be G or A; HCDR3: SPLISMDASDFNS; or HCDR1: X1X2AYTMX3, where X1 is empty or L, X2 is empty or F, and X3 is A or G; HCDR2:SLWWNX 48 X 49 ATYYADSVKG, X 48 For D or E, X 49 It can be G or A; HCDR3: KAGX4YX5YNRAEAX6X 45 S, X4 is S, Y, or W, X5 is D or N, X6 is F or Y, X 45 For T or R; or HCDR1: VAGX7D, where X7 is C or S; HCDR2: RVMPDX8VRTYAESVKG, where X8 is G or A; HCDR3: HFWARDY.

[0061] On the other hand, this application proposes an antibody or an antigen-binding fragment thereof. According to embodiments of this application, the antibody or antigen-binding fragment thereof includes HCDR1, HCDR2, and HCDR3; wherein: HCDR1: NYVMG; HCDR2: TITWX 46 X 47 GTYYADSVKG, X 46 For N or Q, X 47 It can be G or A; HCDR3: SPLISMDASDFNS; or HCDR1: X1X2AYTMX3, where X1 is empty or L, X2 is empty or F, and X3 is A or G; HCDR2:SLWWNX 48 X 49 ATYYADSVKG, X 48 For D or E, X 49 It can be G or A; HCDR3: KAGX4YX5YNRAEAX6TS, where X4 is S, Y, or W, X5 is D or N, and X6 is F or Y; or HCDR1: VAGX7D, where X7 is C or S; HCDR2: RVMPDX8VRTYAESVKG, where X8 is G or A; HCDR3: HFWARDY.

[0062] The antibody or its antigen-binding fragment of this application has high CD28 binding activity and safety.

[0063] It should be noted that the HCDRs mentioned above in this application are obtained according to the Kabat numbering system. However, those skilled in the art are fully capable of converting the sequence of the sequence listing into HCDRs numbered according to other numbering systems, all of which are within the scope of protection of this application.

[0064] The antibodies or antigen-binding fragments thereof described in the first, second, and third aspects of this application exhibit high CD28 binding activity and safety. In particular, while maintaining antibody activity, the aforementioned antibodies or antigen-binding fragments also possess first-signal dependence (they do not activate T cells in the absence of CD3 stimulation), demonstrating excellent safety.

[0065] According to embodiments of this application, the antibody or its antigen-binding fragment described in the second or third aspect may further include at least one of the following technical features: According to embodiments of this application, the antibody or its antigen-binding fragment is HCDR1, HCDR2, or HCDR3 as shown in the table below:

[0066] It should be noted that the HCDRs mentioned above in this application are obtained according to the Kabat numbering system. This application exemplarily demonstrates HCDRs of the above antibodies numbered using other numbering systems. HCDRs of other monoclonal antibodies numbered using different numbering systems for the heavy chain variable regions (amino acid sequences such as those shown in any one of SEQ ID NO: 1~15 or SEQ ID NO: 150~153) are also within the scope of protection of this application. See Table A2 for details: Table A1. HCDRs under various definition methods

[0067] According to embodiments of this application, it further includes at least one of HFR1, HFR2, HFR3, and HFR4; Wherein, at least a portion of at least one of HFR1, HFR2, HFR3 and HFR4 is derived from at least one of alpaca-derived antibodies, mouse-derived antibodies, primate-derived antibodies, bovine-derived antibodies, equine-derived antibodies, dairy bovine-derived antibodies, porcine-derived antibodies, sheep-derived antibodies, goat-derived antibodies, canine-derived antibodies, feline-derived antibodies, rabbit-derived antibodies, donkey-derived antibodies, deer-derived antibodies, mink-derived antibodies, chicken-derived antibodies, duck-derived antibodies, goose-derived antibodies or mutants thereof.

[0068] In this article, the “frame region” or “FR” region includes the heavy chain frame region, which refers to the region in the antibody heavy chain variable region (which can be represented as VH) other than the CDR; wherein, the heavy chain frame region is represented by “HFR” and can be further subdivided into adjacent regions separated by CDR, including HFR1, HFR2, HFR3 and HFR4 frame regions.

[0069] As used in this paper, the heavy chain variable region is obtained by connecting the following numbered CDRs and FRs in the following combination: HFR1-HCDR1-HFR2-HCDR2-HFR3-HCDR3-HFR4.

[0070] According to embodiments of this application, at least a portion of the HFR1, HFR2, HFR3, and HFR4 are derived from alpaca-derived antibodies or human-derived antibodies.

[0071] According to embodiments of this application, HFR1 has an amino acid sequence as shown in DVQLQESGGGLVQAGGSLRLSCATSGRTFV or an amino acid sequence having at least 90% homology with it. HFR2 has an amino acid sequence as shown in WFRQAPGKEREFVA or an amino acid sequence that is at least 85% homologous to it. HFR3 has an amino acid sequence as shown in RFTISDDRPKNTVYLQMNSLKPEDTGVYYCAA or an amino acid sequence with at least 85% homology to it. HFR4 has an amino acid sequence as shown in WGQGTQVTVSS or an amino acid sequence that is at least 90% homologous to it. According to an embodiment of this application, HFR1: DVQLX9ESGGGX 10 VQX 11GGSLRLSCATSGRTFV, X9 is Q or V, X 10 For L or V, X 11 It can be A or P; HFR2: WFRQAPGKX 12 X 13 EFVA, X 12 For E or G, X 13 For L or R; HFR3: RFTISDDRX 14 KNTVYLQMNSLX 15 X 16 EDTX 17 VYYCAA, X 14 For P or S, X 15 For K or R, X 16 For P or A, X 17 It can be G or A; HFR4: WGQGTX 18 VTVSS, X 18 It can be Q or T.

[0072] According to the embodiments of this application, HFR1: QVQLVESGGGVVQPGGSLRLSCATSGRTFV (SEQ ID NO: 98), HFR2: WFRQAPGKEREFVA (SEQ ID NO: 99), HFR3: RFTISDDRSKNTVYLQMNSLRAEDTAVYYCAA (SEQ ID NO: 100), HFR4: WGQGTLVTVSS (SEQ ID NO: 101).

[0073] According to the embodiments of this application, HFR1: QVQLVESGGGVVQPGGSLRLSCATSGRTFV (SEQ ID NO:102), HFR2: WFRQAPGKGLEFVA (SEQ ID NO:103), HFR3: RFTISDDRSKNTVYLQMNSLRAEDTAVYYCAA (SEQ ID NO:104), HFR4: WGQGTLVTVSS (SEQ ID NO:105).

[0074] According to an embodiment of this application, HFR1: DVQLQESGGGLVQAGGSLRLLCAASGSTFF (SEQ ID NO: 106), HFR2: WFRQAPGKEREFVA (SEQ ID NO:107), HFR3: RFTVSRDNAENTVFLQMNSLKAEDTAVYYCGA (SEQ ID NO: 108), HFR4: WGRGTQVTVS (SEQ ID NO: 109). According to an embodiment of this application, HFR1: DVQLVESGGGLVQAGDSLRLSCAASGGTLF (SEQ ID NO: 110), HFR2:WFRQAPGKEREFVG (SEQ ID NO:111), HFR3: RFTISRGNAENTVFLQMNSLKAEDTAVYYCAA (SEQ ID NO: 112), HFR4: WGQGTQVTVS (SEQ ID NO: 113).

[0075] According to embodiments of this application, HFR1 has an amino acid sequence as shown in DVQLQESGGGLVQAGGSLRLLCAASISGRT or an amino acid sequence having at least 85% homology with it. HFR2 has an amino acid sequence as shown in WFRQAPGKEREFVA or an amino acid sequence that is at least 85% homologous to it. HFR3 has an amino acid sequence as shown in RFTISRDNAENTVFLEMNNLKAEDTAVYYCAA or an amino acid sequence with at least 75% homology to it. HFR4 has an amino acid sequence as shown in WGQGTQVT or an amino acid sequence that is at least 60% homologous to it.

[0076] According to an embodiment of this application, HFR1: DVQLX 19 ESGGGX 20 VQX 21 GGSLRLX 22 CAASISGRT, X 19 For Q or V, X 20 For L or V, X 21 For A or P, X 22 For L or S; HFR2: WFRQAPGKX 23 X 24 EFVA, X 23 For E or G, X 24 For R or L; HFR3: RFTISRDNX 25 X 26 NTX 27 X28 LX 29 MNX 30 LX 31 AEDTAVYYCAA, X 25 For A or S, X 26 For E or K, X 27 For V or L, X 28 For F or Y, X 29 For E or Q, X 30 For N or S, X 31 For K or R; HFR4: WGQGTX 32 VTX 33 X 34 X 35 X 32 For Q or L, X 33 Empty or V, X 34 Empty or S, X 35 It can be empty or S.

[0077] According to the embodiments of this application, HFR1: QVQLVESGGGVVQPGGSLRLSCAASISGRT (SEQ ID NO:114), HFR2: WFRQAPGKGLEFVA (SEQ ID NO:115), HFR3: RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAA (SEQ ID NO:116), HFR4: WGQGTLVTVSS (SEQ ID NO:117).

[0078] According to the embodiments of this application, HFR1: QVQLVESGGGVVQPGGSLRLSCAASISGRT (SEQ ID NO:118), HFR2: WFRQAPGKEREFVA (SEQ ID NO:119), HFR3: RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAA (SEQ ID NO:120), HFR4: WGQGTLVTVSS (SEQ ID NO:121).

[0079] According to the embodiments of this application, HFR1: QVQLVESGGGVVQPGGSLRLSCAASISGRT (SEQ ID NO:122), HFR2: WFRQAPGKEREFVA (SEQ ID NO:123), HFR3: RFTISRDNSKNTVYLQMNSLRAEDTAVYYCAA (SEQ ID NO:124), HFR4: WGQGTLVTVSS (SEQ ID NO:125).

[0080] According to the embodiments of this application, HFR1: QVQLVESGGGVVQPGGSLRLSCAASISGRT (SEQ ID NO:126), HFR2: WFRQAPGKGLEFVA (SEQ ID NO:127), HFR3: RFTISRDNSKNTVYLQMNSLRAEDTAVYYCAA (SEQ ID NO:128), HFR4: WGQGTLVTVSS (SEQ ID NO:129).

[0081] According to the embodiments of this application, HFR1: QVQLVESGGGVVQPGGSLRLSCAASISGRT (SEQ ID NO:130), HFR2: WFRQAPGKEREFVA (SEQ ID NO:131), HFR3: RFTISRDNSKNTVYLEMNSLRAEDTAVYYCAA (SEQ ID NO:132), HFR4: WGQGTLVTVSS (SEQ ID NO:133).

[0082] According to embodiments of this application, HFR1 has an amino acid sequence as shown in QVQLVESGGGLVQPGGSLRLSCAASGSIFS or an amino acid sequence having at least 95% homology with it. HFR2 has an amino acid sequence as shown in WYREAPGKQRDWVA or an amino acid sequence that is at least 90% homologous to it. HFR3 has an amino acid sequence as shown in RFTISTDNTFSTVYLEMNSLKPEDTAHYYCKT or an amino acid sequence with at least 85% homology to it. HFR4 has an amino acid sequence as shown in WGQGTQVTVLR or an amino acid sequence that is at least 70% homologous to it.

[0083] According to an embodiment of this application, HFR1: QVQLVESGGGX 36 VQPGGSLRLSCAASGSIFS, X 36 For L or V; HFR2: WYREAPGKQRX 37 WVA, X 37 For D or R; HFR3:RFTISTDNX 38 FSTVYLEMNSLX 39 X 40 EDTAX 41 YYCKT, X 38 For T or S, X39 For K or R, X 40 For P or A, X 41 For H or V; HFR4: WGQGTX 42 VTVX 43 X 44 X 42 For Q or L, X 43 For L or S, X 44 It can be R or S.

[0084] According to the embodiments of this application, HFR1: QVQLVESGGGVVQPGGSLRLSCAASGSIFS (SEQ ID NO:134), HFR2: WYREAPGKQREWVA (SEQ ID NO:135), HFR3: RFTISTDNSFSTVYLEMNSLRAEDTAVYYCKT (SEQ ID NO:136), HFR4: WGQGTLVTVSS (SEQ ID NO:137).

[0085] According to the embodiments of this application, HFR1: QVQLVESGGGVVQPGGSLRLSCAASGSIFS (SEQ ID NO:138), HFR2: WYREAPGKQREWVA (SEQ ID NO:139), HFR3: RFTISTDNSFSTVYLEMNSLKAEDTAVYYCKT (SEQ ID NO:140), HFR4: WGQGTLVTVSS (SEQ ID NO:141).

[0086] According to the embodiments of this application, HFR1: QVQLVESGGGVVQPGGSLRLSCAASGSIFS (SEQ ID NO:142), HFR2: WYREAPGKQREWVA (SEQ ID NO:143), HFR3: RFTISTDNSFSTVYLEMNSLKAEDTAHYYCKT (SEQ ID NO:144), HFR4: WGQGTLVTVSS (SEQ ID NO:145).

[0087] According to embodiments of this application, the antibody or its antigen-binding fragment has a heavy chain variable region as shown by any one of the amino acid sequences of SEQ ID NO:1~15, SEQ ID NO:150~153 and an amino acid sequence having at least 85% homology with it.

[0088] According to embodiments of this application, the antibody or its antigen-binding fragment has a heavy chain variable region as shown by any one of the amino acid sequences of SEQ ID NO: 1-5, 8, 14-15 and an amino acid sequence having at least 85% homology with it.

[0089] According to embodiments of this application, the antibody or its antigen-binding fragment has a heavy chain variable region as shown in any one of the amino acid sequences of SEQ ID NO:2-3.

[0090] According to embodiments of this application, the antibody or its antigen-binding fragment has a heavy chain variable region as shown in the amino acid sequence of SEQ ID NO: 1, or a heavy chain variable region shown in an amino acid sequence having at least 90% homology with it. Exemplarily, the heavy chain variable region shown in the amino acid sequence of SEQ ID NO: 6 (R4572) or SEQ ID NO: 9 (R4570) has at least 90% homology with the heavy chain variable region shown in the amino acid sequence of SEQ ID NO: 1 (FR2-19).

[0091] According to embodiments of this application, the antibody or its antigen-binding fragment has a heavy chain variable region as shown in the amino acid sequence of SEQ ID NO:4, or a heavy chain variable region shown in an amino acid sequence having at least 85% homology with it. Exemplarily, the heavy chain variable regions shown in amino acid sequences such as SEQ ID NO:7 (R4589), SEQ ID NO:10 (R4585), SEQ ID NO:11 (R4586), SEQ ID NO:12 (R4587), or SEQ ID NO:13 (R4588) all have at least 85% homology with the heavy chain variable region shown in the amino acid sequence of SEQ ID NO:4 (S3-62).

[0092] According to embodiments of this application, the antibody or its antigen-binding fragment has a heavy chain variable region as shown in the amino acid sequence of SEQ ID NO:5, or a heavy chain variable region shown in an amino acid sequence having at least 90% homology with it. Exemplarily, the heavy chain variable regions shown in amino acid sequences such as SEQ ID NO:8 (R4697), SEQ ID NO:14 (R4698), or SEQ ID NO:15 (R4699) all have at least 90% homology with the heavy chain variable regions shown in amino acid sequences such as SEQ ID NO:5 (S3-44).

[0093] According to embodiments of this application, the antibody or its antigen-binding fragment has a heavy chain variable region as shown in any one of the amino acid sequences of SEQ ID NO:8, 14-15, or a heavy chain variable region shown in an amino acid sequence having at least 90% homology with it. For example, the heavy chain variable region shown in the amino acid sequence of SEQ ID NO:5 (S3-44) has at least 90% homology with the heavy chain variable regions shown in the amino acid sequences of SEQ ID NO:8 (R4697), SEQ ID NO:14 (R4698), or SEQ ID NO:15 (R4699).

[0094] According to embodiments of this application, the antibody or its antigen-binding fragment has a heavy chain variable region as shown in any one of the amino acid sequences of SEQ ID NO: 6 to 15, or a heavy chain variable region shown in an amino acid sequence having at least 85% homology with it.

[0095] According to embodiments of this application, the antibody or its antigen-binding fragment has a heavy chain variable region as shown in any one of the amino acid sequences of SEQ ID NO: 6 to 15.

[0096] According to embodiments of this application, the antibody or its antigen-binding fragment described in the first, second, or third aspects may further include at least one of the following technical features: According to embodiments of this application, the antibody or its antigen-binding fragment further includes CH2 and CH3 of the heavy chain constant region.

[0097] According to embodiments of this application, at least a portion of the heavy chain constant region is derived from at least one of alpaca-derived antibodies, mouse-derived antibodies, primate-derived antibodies, bovine-derived antibodies, equine-derived antibodies, dairy bovine-derived antibodies, porcine-derived antibodies, sheep-derived antibodies, goat-derived antibodies, canine-derived antibodies, cat-derived antibodies, rabbit-derived antibodies, donkey-derived antibodies, deer-derived antibodies, mink-derived antibodies, chicken-derived antibodies, duck-derived antibodies, goose-derived antibodies, or mutants thereof, preferably from alpaca-derived antibodies or human antibodies.

[0098] According to embodiments of this application, the heavy chain constant region includes a heavy chain constant region selected from IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, or IgD. According to an embodiment of this application, the N end of the heavy chain constant region is connected to the C end of the heavy chain variable region.

[0099] According to an embodiment of this application, the heavy chain constant region is selected from hIgG1.

[0100] In antibody drug development, post-translational modification (PTM) of the antibody complementarity-determining region (CDR) is a key preventative molecular optimization strategy. Its purpose is to prospectively eliminate known or predicted chemical instabilities in the sequence that may impair antibody druggability before entering full-scale preclinical development, thereby obtaining more stable and reliable candidate molecules. The PTM modification of the humanized antibody in this invention is based on this strategy. In some specific embodiments, this application maintains antigen-binding activity or minimizes its disruption while effectively eliminating specific PTM risks (such as deamidation, isomerization, or unpaired disulfide bond formation). In some specific embodiments, the PTM-modified variants maintain binding activity comparable to the parent antibody. Based on this, those skilled in the art can reasonably expect that, compared to the original sequence, the modified variants have potential advantages in improving antibody stability, affinity, specificity, immunogenicity, or pharmacokinetic properties. This invention provides an optimized, lower-risk material basis for subsequent development by providing these rationally designed and functionally validated PTM-modified variant sequences. Based on the sequence and binding activity data disclosed in this specification, those skilled in the art can prepare the antibodies and further characterize and confirm their improved properties using conventional drugability analysis models and methods. It should be noted that the PTM modified variants listed in the embodiments of this application are merely examples. Based on the teachings of this invention, other reasonable amino acid substitutions made by those skilled in the art for the CDR region of the antibodies to eliminate the same or similar PTM risks should also fall within the scope of protection of this invention. Those skilled in the art will understand that the features and advantages described above with respect to the antibodies or their antigen-binding fragments described in the first aspect (such as the heavy chain variable region and / or light chain variable region as defined in the first aspect) are also applicable to the antibodies described in the second and third aspects, and will not be repeated here.

[0101] biomaterials In a fourth aspect, this application provides a biomaterial comprising any one of the following (i) to (vii): (i) A nucleic acid molecule that encodes an antibody or an antigen-binding fragment thereof as described in any one of the first to third aspects; According to embodiments of this application, the nucleic acid includes DNA or RNA.

[0102] It should be noted that, for the nucleic acids mentioned herein, those skilled in the art should understand that they actually include any one or both of the complementary double strands. For convenience, although only one strand is given in most cases herein, the other complementary strand is also disclosed. Furthermore, the molecular sequences in this application include DNA or RNA forms; disclosure of one implies that the other is also disclosed.

[0103] Those skilled in the art will understand that the features and advantages described above for the antibody or its antigen-binding fragment also apply to this nucleic acid, and will not be repeated here.

[0104] (ii) A vector comprising the nucleic acid molecule described in (i); When linking the nucleic acid described in the fourth aspect to the aforementioned vector, the nucleic acid can be directly or indirectly connected to control elements on the vector, as long as these control elements can control the translation and expression of the nucleic acid. Of course, these control elements can be directly derived from the vector itself or be exogenous, i.e., not derived from the vector itself. Naturally, the connection between the nucleic acid and the control elements simply needs to be operably established.

[0105] In this document, "operably ligated" refers to ligating a foreign gene to a vector, enabling the control elements within the vector, such as transcriptional control sequences and translational control sequences, to perform their intended functions of regulating the transcription and translation of the foreign gene. Commonly used vectors include plasmids, bacteriophages, etc. According to some specific embodiments of this application, after the vector is introduced into suitable recipient cells, the expression of the aforementioned antibody or its antigen-binding fragment can be effectively achieved under the mediation of a regulatory system, thereby enabling the large-scale in vitro production of the antibody or its antigen-binding fragment.

[0106] According to embodiments of this application, the vector may refer to a cloning vector, which can be obtained by operatively ligating the nucleic acid to a commercially available vector (such as a plasmid or viral vector). The vector in this application is not particularly limited; commonly used plasmids such as pSeTag2, PEE14, and pMH3 can be used.

[0107] In some optional embodiments of this application, the vector is a eukaryotic expression vector, a prokaryotic expression vector, a virus, or a bacteriophage.

[0108] In some optional embodiments of this application, the expression vector is a plasmid expression vector or a lentiviral expression vector.

[0109] Those skilled in the art will understand that the features and advantages described above for antibodies or their antigen-binding fragments and nucleic acids also apply to this vector, and will not be repeated here.

[0110] (iii) A cell or host comprising: (i) the nucleic acid molecule or (ii) the vector; or expressing an antibody or an antigen-binding fragment thereof as described in any one of the first to third aspects; According to embodiments of this application, the aforementioned antibody or its antigen-binding fragment can be effectively expressed within the cell or host under suitable conditions.

[0111] According to embodiments of this application, the cells are obtained by introducing the vector described in the fifth aspect into a cell or host.

[0112] It should be noted that the cells or hosts used in this application are not particularly limited and can be prokaryotic cells, eukaryotic cells, or bacteriophages. The prokaryotic cells can be Escherichia coli, Bacillus subtilis, Streptomyces, or Proteus mirabilis, etc. The eukaryotic cells include fungi such as Pichia pastoris, Saccharomyces cerevisiae, Schizosoma, and Trichoderma; insect cells such as armyworms; plant cells such as tobacco; and mammalian cells such as BHK cells, CHO cells, COS cells, and myeloma cells.

[0113] In one optional embodiment of this application, the cells are mammalian cells, including BHK cells, CHO cells, NSO cells or COS cells, but do not include animal germ cells, fertilized eggs or embryonic stem cells.

[0114] (iv) A conjugate, characterized in that it comprises: an antibody or an antigen-binding fragment thereof as described in any one of the first to third aspects, and a conjugate portion therewith; As previously known, the aforementioned antibody or antigen-binding fragments can bind to CD28. Therefore, conjugates containing the aforementioned antibody or antigen-binding fragments can also bind to CD28 and can be used to detect CD28 or detect cells expressing CD28, or to activate T cells for the prevention and treatment of related diseases.

[0115] According to embodiments of this application, the coupling portion includes a selection from purification tags or labels; According to embodiments of this application, the purification label or marker includes at least one selected from colloidal gold, radioactive labeling, luminescent substances, colored substances, enzymes, biotin / avidin, and spin labeling. According to embodiments of this application, the purification label or marker includes at least one selected from fluorescent markers, chromophore markers, and electron-dense markers; According to embodiments of this application, the purification label or marker includes one or more selected from radioactive isotopes, fluorophores, rhodamine and its derivatives, luciferase, luciferin, horseradish peroxidase, alkaline phosphatase, β-galactosidase, glucosylamylase, lysozyme, carbohydrate oxidase, glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase. According to embodiments of this application, the coupling portion includes at least one selected from magnetic microspheres, plastic microspheres, plastic microparticles, microporous plates, glass, capillaries, nylon, and nitrocellulose membranes; According to embodiments of this application, the above-mentioned coupling may further include at least one of the following additional technical features: According to embodiments of this application, the coupling portion is selected from at least one of a carrier, a bioactive protein or a fragment thereof, a bioactive polypeptide or a fragment thereof, a modifier, and a chemotherapeutic agent.

[0116] In this document, the carrier can be a substance capable of suspension or dispersion in a liquid phase (e.g., solid-phase carriers such as particles and magnetic beads), or a solid phase capable of containing or carrying a liquid phase (e.g., supports such as plates, membranes, and test tubes, as well as containers such as well plates, microfluidic paths, glass capillaries, nanopillars, and monolithic columns); it can also be a labeling carrier for labeling antibodies, such as enzymes (e.g., peroxidase, alkaline phosphatase, luciferin, β-galactosidase), affinity substances (e.g., one of streptavidin and biotin, one of complementary sense and antisense nucleic acids), fluorescent substances (e.g., luciferin, fluorescein isothiocyanate, rhodamine, green fluorescent protein, red fluorescent protein), luminescent substances (e.g., luciferin, aequorin, acridinium ester, tris(2,2'-bipyridine)ruthenium, luminol), and radioactive isotopes (e.g., 3 H, 14 C 32 P, 35 S, 125 I) and gold colloids, etc.

[0117] In some alternative embodiments of this application, the carrier includes a marker.

[0118] According to embodiments of this application, the label includes at least one selected from colloidal gold, radioactive labeling, luminescent material, colored material, enzyme, biotin / avidin protein, and spin labeling.

[0119] According to embodiments of this application, the marker includes at least one selected from fluorescent markers, chromophore markers, and electron-dense markers.

[0120] According to embodiments of this application, the marker includes one or more selected from radioactive isotopes, fluorophores, rhodamine and its derivatives, luciferase, luciferin, horseradish peroxidase, alkaline phosphatase, β-galactosidase, glucosylamylase, lysozyme, carbohydrate oxidase, glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase.

[0121] According to embodiments of this application, the coupling portion includes at least one selected from magnetic microspheres, plastic microspheres, plastic microparticles, microporous plates, glass, capillaries, nylon, and nitrocellulose membranes.

[0122] According to embodiments of the present invention, the bioactive protein or fragment thereof includes at least one selected from protein tags, protein toxins or fragment thereof, tumor necrosis factor or fragment thereof, interferon or fragment thereof, biological response regulators or fragment thereof, and Fc fragments.

[0123] In this article, "protein tag" generally refers to a polypeptide or protein fused together with a target protein (antibody or antigen-binding fragment) for expression, detection, retrieval, or purification of the target protein. Examples include, but are not limited to, His tags (also known as His-Tag, sequence HHHHHH), Flag tags (also known as Flag-Tag, sequence DYKDDDDK), GST tags (also known as GST-Tag, glutathione thiotransferase tag), MBP tags (also known as MBP-Tag, maltose-binding protein tag), SUMO tags, and C-Myc tags.

[0124] In this document, "toxin" generally refers to substances toxic to the host, including protein toxins and non-protein toxins. Protein toxins include, but are not limited to, abrin, ricin A, Pseudomonas exotoxin, and diphtheria toxin. In this invention, the protein toxin is preferably an enzymatic protein toxin.

[0125] In this article, "tumor necrosis factor" generally refers to substances that can cause hemorrhagic necrosis in various tumors, including but not limited to TNF-α and TNF-β.

[0126] In this article, "interferon" generally refers to a glycoprotein that has the ability to directly kill or inhibit viruses. This includes, but is not limited to, IFN-α, IFN-β, and IFN-γ.

[0127] In this article, "biological response modulators" generally refers to a class of protein substances that enhance the body's anti-tumor effects directly or indirectly through the immune system. These include, but are not limited to, lymphokines, IL-2, IL-6, IL-10, and GM-CSF.

[0128] In this document, "Fc fragment" generally refers to the Fc region of IgG (e.g., IgG1, IgG2, IgG3, or IgG4 subtypes), IgA1, IgA2, IgD, IgE, or IgM, including CH2, CH3 regions and optionally hinge regions. Preferably, the IgG, IgA1, IgA2, IgD, IgE, or IgM are derived from alpaca, mouse, human, or primate sources.

[0129] Those skilled in the art will understand that the features and advantages described above for the antibody or its antigen-binding fragment also apply to this conjugate, and will not be repeated here.

[0130] In an eighth aspect of this application, a reagent or kit is provided. According to embodiments of this application, the reagent or kit comprises: an antibody or antigen-binding fragment thereof as described in the first, second, or third aspect, or a conjugate as described in the seventh aspect. As is previously known, the aforementioned antibody or antigen-binding fragment can bind to CD28. Therefore, a reagent or kit containing the aforementioned antibody or antigen-binding fragment can also bind to CD28 and can be used to detect CD28 or detect cells expressing CD28.

[0131] In some alternative embodiments of this application, the products in any of the above aspects, such as, but not limited to, anti-CD28 antibodies or antigen-binding fragments thereof in reagents, kits, blocking agents, and pharmaceutical compositions, may be conjugated with at least one diagnostic agent and / or therapeutic agent to form an immunoconjugate.

[0132] The diagnostic agent is selected from one or more of the following: radioactive contrast agents, paramagnetic ions, metals, fluorescent labels, chemiluminescent labels, ultrasound contrast agents, and photosensitizers. The therapeutic agent is selected from one or more of the following: cytotoxic agents, drugs, radionuclides, boron atoms, immunomodulators, anti-apoptotic agents, photosensitizing therapeutic agents, immunoconjugates, and oligonucleotides.

[0133] Radioactive nuclides include, but are not limited to, 110 In、 111 In、 177 Lu、 18 F, 52 Fe、 62 Cu、 64 Cu、 67 Cu、 67 Ga、 68 Ga、 86 Y、 90 Y、 89 Zr、 94 mTc, 94 Tc, 99 mTc, 120 I, 123 I, 124 I, 125 I, 131 I, 154-158 Gd, 32 P, 11 C 13 N、 15 O、 186 Re、 188 Re、51 Mn, 52 mMn, 55 Co、 72 As、 75 Br、 76 Br、 82 mRb and 83 One or more of Sr.

[0134] Paramagnetic ions include, but are not limited to, one or more of chromium (III), manganese (II), iron (III), cobalt (II), nickel (II), copper (II), neodymium (III), samarium (III), ytterbium (III), gadolinium (III), vanadium (II), terbium (III), dysprosium (III), holmium (III) and erbium (III).

[0135] Fluorescent markers include, but are not limited to, Alexa 350, Alexa 405, Alexa 430, Alexa 488, Alexa 555, Alexa 647, AMCA, aminoacridine, BODIPY 630 / 650, BODIPY 650 / 665, BODIPY-FL, BODIPY-R6G, BODIPY-TMR, BODIPY-TRX, 5-carboxy-4′,5′-dichloro-2′,7′-dimethoxyfluorescein, 5-carboxy-2′,4′,5′,7′-tetrachlorofluorescein, 5-carboxyfluorescein, 5-carboxyrhodamine, 6-carboxyrhodamine, 6-carboxytetramethylrhodamine, and Cascade. Blue, Cy2, Cy3, Cy5, Cy7, 6-FAM, Dansyl chloride, Fluorescein, HEX, 6-JOE, NBD (7-nitrobenzo-2-oxa-1,3-diazole), Oregon Green 488, Oregon Green 500, Oregon Green 514, Pacific Blue, Phthalic acid, Terephthalic acid, Isophthalic acid, Cresol Violet, Cresol Blue Violet, Brilliant Cresol Blue, p-Aminobenzoic acid, Erythrosine, Phthalocyanine, Azocyanine, Anthocyanin, Xanthine, Succinyl fluorescein, Rare earth metal cavitary compounds, Tribispyridyldiamine europium, europium cavitary compounds or chelates, Diamine, Dianthocyanin, La Jolla Blue dye, Allococyanin B. Phycocyanin C. Phycocyanin R. Thiamine, Phycoerythrin, Phycoerythrin R. REG. Rhodamine Green, Rhodamine Isothiocyanate, Rhodamine Red, ROX, TAMRA, TET, TRIT (Tetramethylrhodamine isothiol), Tetramethylrhodamine, and Texas Red.

[0136] Oligonucleotides include, but are not limited to, one or more of shRNA, miRNA, and siRNA.

[0137] Drugs include, but are not limited to, methotrexate, fluorouracil, mercaptopurine, hydroxyurea, cytarabine, nitrogen mustard, cyclophosphamide, thiotepa, cisplatin, mitomycin, bleomycin, camptothecin, podophyllotoxin, actinomycin D, doxorubicin, daunorubicin, vincristine, paclitaxel, cephalotaxine alkaloids, and L-asparaginase.

[0138] Immunomodulators include, but are not limited to, one or more of the following: cytokines, chemokines, stem cell growth factors, lymphotoxins, hematopoietic factors, colony-stimulating factors (CSF), interferons, erythropoietin, thrombopoietin, tumor necrosis factor (TNF), interleukins (IL), granulocyte-colony-stimulating factor (G-CSF), granulocyte-macrophage-colony-stimulating factor (GM-CSF), and stem cell growth factors.

[0139] Radioactive nuclides include, but are not limited to, 111 In、 111 At、 177 Lu、 211 Bi、 212 Bi、 213 Bi、 211 At、 62 Cu、 67 Cu、 90 Y、 125 I, 131 I, 133 I, 32 P, 33 P, 47 Sc、 111 Ag、 67 Ga、 153 Sm、 161 Tb, 152 Dy、 166 Dy、 161 Ho、 166 Ho、 186 Re、 188 Re、 189 Re、 211 Pb, 212 Pb, 223 Ra、 225 Ac、 77 As、 89 Sr、 99 Mo、 105 Rh、 149 Pm, 169 Er、 194 Ir、 58 Co、 80 mBr、 99 mTc, 103 mRh、109 Pt, 119 Sb, 189 mOs, 192 Ir、 219 Rn、 215 Po、 221 Fr、 255 Fm、 11 C 13 N、 15 O、 75 Br、 198 Au、 199 Au、 224 Ac、 77 Br、 113 mIn, 95 Ru、 97 Ru、 103 Ru、 105 Ru、 107 Hg, 203 Hg, 121 mTe, 122 mTe, 125 mTe, 165 Tm、 167 Tm、 168 Tm、 197 Pt, 109 Pd, 142 Pr、 143 Pr、 161 Tb, 57 Co、 58 Co、 51 Cr 59 Fe、 75 Se、 201 Tl、 76 Br and 169 One or more of Yb.

[0140] Those skilled in the art will understand that the features and advantages described above for the antibody or its antigen-binding fragment also apply to this reagent or kit, and will not be repeated here.

[0141] (v) A reagent or kit, characterized in that it comprises: an antibody or antigen-binding fragment thereof as described in any one of the first to third aspects, or a conjugate as described in (iv).

[0142] It should be noted that the "suitable conditions" mentioned in this application refer to conditions suitable for the expression of the antibody or its antigen-binding fragment described in this application. Those skilled in the art will readily understand that suitable conditions for the expression of the antibody or its antigen-binding fragment include, but are not limited to, suitable transformation or transfection methods, suitable transformation or transfection conditions, healthy cell state, suitable cell density, suitable cell culture environment, and suitable cell culture time. The term "suitable conditions" is not particularly limited, and those skilled in the art can optimize the optimal conditions for the expression of the antibody or its antigen-binding fragment according to the specific environment of their laboratory.

[0143] Those skilled in the art will understand that the features and advantages described above for antibodies or their antigen-binding fragments, nucleic acids, and vectors also apply to this cell or host, and will not be repeated here.

[0144] Pharmaceutical Composition In a fifth aspect of this application, a pharmaceutical composition is provided. According to embodiments of this application, the pharmaceutical composition comprises the antibody or antigen-binding fragment thereof described in the first, second, or third aspect, and the biological material described in the fourth aspect. The antibodies or antigen-binding fragments thereof described in the first, second, and third aspects of this application possess high CD28 binding activity and safety. Therefore, conjugates containing the aforementioned antibodies or antigen-binding fragments can also bind to CD28, activate T cells, and prevent and treat related diseases.

[0145] According to embodiments of this application, the pharmaceutical composition may further include at least one of the following technical features: According to embodiments of this application, the pharmaceutical composition further comprises pharmaceutically acceptable excipients.

[0146] According to embodiments of this application, the excipients include, but are not limited to, one or more pharmaceutically acceptable diluents, stabilizers, or pH adjusters.

[0147] According to embodiments of this application, the pharmaceutical composition is an injection.

[0148] It should be noted that the pharmaceutical composition includes combinations that are separate in time and / or space, as long as they can work together to achieve the purpose of this application. For example, the components contained in the composition may be administered to the subject as a whole or separately. When the components contained in the composition are administered to the subject separately, the individual components may be administered to the subject simultaneously or sequentially.

[0149] The pharmaceutical composition of this application contains a safe and effective amount of the active ingredient of this application and pharmaceutically acceptable excipients. Such excipients include (but are not limited to): saline, buffer solutions, glucose, water, glycerol, ethanol, and combinations thereof. Generally, pharmaceutical formulations should be matched to the route of administration; the dosage forms of the pharmaceutical composition of this application are injections, oral formulations (tablets, capsules, oral liquids), transdermal formulations, and sustained-release formulations. For example, it can be prepared using physiological saline or an aqueous solution containing glucose and other excipients by conventional methods. The pharmaceutical composition is preferably manufactured under aseptic conditions.

[0150] The effective amount of the active ingredient described in this application may vary depending on the administration method and the severity of the disease to be treated. A preferred effective amount can be determined by those skilled in the art based on various factors (e.g., through clinical trials). These factors include, but are not limited to: pharmacokinetic parameters of the active ingredient, such as bioavailability, metabolism, and half-life; the severity of the disease to be treated, the patient's weight, the patient's immune status, and the route of administration. For example, due to the urgency of the treatment condition, several separate doses may be administered daily, or the dose may be reduced proportionally.

[0151] Pharmaceutically acceptable excipients described in this application include (but are not limited to): water, saline, liposomes, lipids, proteins, protein-antibody conjugates, peptides, cellulose, nanogels, or combinations thereof. The choice of carrier should be matched to the route of administration, as is well known to those skilled in the art.

[0152] Those skilled in the art will understand that the features and advantages described above for the antibody or its antigen-binding fragment, nucleic acid, vector, and cell or host also apply to this pharmaceutical composition, and will not be repeated here.

[0153] use In a sixth aspect of this application, the use of the antibody or antigen-binding fragment thereof described in the first, second or third aspect, the biological material described in the fourth aspect, or the pharmaceutical composition described in the fifth aspect in the preparation of a medicament for the treatment, prevention or relief of diseases, symptoms or conditions associated with tumors, inflammation, autoimmune diseases, infections, or immune rejection of organ transplants is provided.

[0154] This application provides for antibodies or antigen-binding fragments thereof as described in the first, second, or third aspect, biological materials as described in the fourth aspect, or pharmaceutical compositions as described in the sixth aspect, for the treatment, prevention, or relief of diseases, symptoms, or conditions associated with tumors, inflammation, autoimmune diseases, infections, or immune rejection in organ transplantation.

[0155] This application proposes the use of the antibody or antigen-binding fragment thereof described in the first, second or third aspect, the biological material described in the fourth aspect, or the pharmaceutical composition described in the fifth aspect in the treatment, prevention or relief of diseases, symptoms or conditions related to tumors, inflammation, autoimmune diseases, infections, or immune rejection of organ transplants.

[0156] The terms “treatment” and “prevention” as used herein, and words derived therefrom, do not necessarily imply 100% or complete treatment or prevention. Rather, different degrees of treatment or prevention exist, and those skilled in the art will recognize that such treatment or prevention has potential benefit or therapeutic effect. Furthermore, the treatment or prevention provided in this application may include treatment or prevention of one or more diseases, such as cancer, or symptoms of a patient. Additionally, for the purposes of this document, “prevention” may encompass delaying the onset of a disease or its symptoms or the patient's condition.

[0157] In a sixth aspect of this application, the use of the antibody or antigen-binding fragment thereof described in the first, second or third aspects, and the biological material described in the fourth aspect in the preparation of a product for detecting CD28 or detecting cells expressing CD28.

[0158] This application provides for antibodies or antigen-binding fragments thereof as described in the first, second, or third aspects, and biological materials as described in the fourth aspect, for detecting CD28 or detecting cells expressing CD28.

[0159] This application proposes the use of the antibodies or antigen-binding fragments thereof described in the first, second or third aspects, and the biological materials described in the fourth aspect in the detection of CD28 or in the detection of cells expressing CD28.

[0160] method In a seventh aspect of this application, a method for treating, preventing, or alleviating a disease, symptom, or condition is provided. According to embodiments of this application, the method includes administering to a subject a pharmaceutically acceptable dose of an antibody or antigen-binding fragment thereof described in the first, second, or third aspect, a biological material described in the fourth aspect, or a pharmaceutical composition described in the fifth aspect.

[0161] It should be noted that the terms "subject," "individual," and "patient" are used interchangeably herein and refer to a mammal being evaluated for treatment and / or being treated. In one implementation, the mammal is a human. The terms "subject," "individual," and "patient" include, but are not limited to, individuals with cancer, individuals with autoimmune diseases, individuals with pathogen infections, etc. Subjects can be humans, but also include other mammals, particularly mammals that can be used as laboratory models of human diseases, such as mice, rats, etc.

[0162] The effective amount of the antibody or its antigen-binding fragment, nucleic acid, vector, cell or host, or pharmaceutical composition described in this application may vary depending on the administration method and the severity of the disease to be treated. A preferred effective amount can be determined by those skilled in the art based on various factors (e.g., through clinical trials). These factors include, but are not limited to: pharmacokinetic parameters of the active ingredient, such as bioavailability, metabolism, and half-life; the severity of the disease to be treated, the patient's weight, the patient's immune status, and the route of administration. For example, due to the urgency of the treatment condition, several separate doses may be administered daily, or the dose may be reduced proportionally.

[0163] In a seventh aspect of this application, a method for detecting CD28 is provided. According to an embodiment of this application, the method includes: contacting the sample to be tested with an antibody or antigen-binding fragment thereof described in the first, second, or third aspect, and the biological material described in the fourth aspect, to form an immune complex.

[0164] According to embodiments of this application, the presence or content of CD28 in the sample to be tested is determined based on the signal of the immune complex.

[0165] According to embodiments of this application, the immune complex further includes a second antibody, which binds to the antibody or its antigen-binding fragment.

[0166] According to an embodiment of this application, the immune complex further includes a second antibody that binds to CD28.

[0167] According to embodiments of this application, the signal includes a fluorescence signal.

[0168] The following will explain the solution of this application with reference to embodiments. Those skilled in the art will understand that the following embodiments are for illustrative purposes only and should not be considered as limiting the scope of this application. Where specific techniques or conditions are not specified in the embodiments, they are performed according to the techniques or conditions described in the literature in the art or according to the product instructions. Reagents or instruments whose manufacturers are not specified are all conventional products that can be obtained commercially.

[0169] Example 1: Material Preparation The target gene encoding human CD28 (Uniprot database ID: P10747) was cloned into a plasmid containing mouse Fc, and then transfected into HEK293 cells for transient expression to obtain hCD28-mFc, which is numbered R3031 (amino acid sequence shown in SEQ ID NO:35).

[0170] Using the sequence encoding human CD28 (Uniprot database ID: P10747) as a template, hCD28 mRNA was prepared by in vitro transcription, and after purification, the mRNA was encapsulated with LNP to prepare the hCD28 mRNA-LNP complex.

[0171] We purchased the cell line 293T-hCD28 (catalog number: KC-0211) that overexpresses human CD28 from Kangyuan Bochuang.

[0172] We purchased an hIgG1 isotype antibody (catalog number: 403501) from Biolegend as a negative control, catalog number R0861.

[0173] A positive antibody (super agonist) for the hIgG4 subtype was prepared based on the antibody sequence (the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO:36, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:37) in international publication number WO2020210392. Its number is R3035.

[0174] A positive nanobody of the hIgG1 subtype, abbreviated as R3796, was prepared based on the antibody sequence (amino acid sequence of the heavy chain variable region as shown in SEQ ID NO:16) in patent number US20230348600A1.

[0175] NKILVKQSPMLVAYDNAVNLSCKYSYNLFSREFRASLHKGLDSAVEVCVVYGNYSQQLQVYSKTGFNCDGKLGNESVTFYLQNLYVNQTDIYFCKIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPVPRDCGCKPCICTVPEVSSVFIFPPKPKDVLTITLTPKVTCVVVDI SKDDPEVQFSWFVDDVEVHTAQTKPREEQFNSTFRSVSELPIMHQDWLNGKEFKCRVNSAAFPAPIEKTISKTKGRPKAPQVYTIPPPKEQMAKDKVSLTCMITNFFPEDITTVEWQWNGQPAENYKNTQPIMDTDGSYFVYSKLNVQKSNWEAGNTFTCSVLHEGLHNHHTEKSLSHSPGK (SEQ ID NO:35); QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYYIHWVRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATLTVDTSISTAYMELSRLRSDDTAVYYCTRSHYGLDWNFDVWGKGTTVTVSS (SEQ ID NO: 36); DIQMTQSPSSSLSASVGDRVTITCQASQNIYVWLNWYQQKPGKAPKLLIYKASNLHTGVPSRFSGSGSGTDFTLTISSLQPEDIATYYCQQGQTYPYTFGQGTKLEIK (SEQ ID NO:37); QVQLVESGGGLVQPGGSTLSCTVTGFSSDNYAIAWFRQAPGKEREGVACINMNGDPYDVDSMKGRFSISRDNSKNTVYLLMNKLTSEDTAVYYCAAESEGHCDGSNSEFDSWGQGTQVTVSS (SEQ ID NO: 16).

[0176] Example 2: Screening of CD28 nanobodies Alpacas were immunized subcutaneously at multiple sites. Recombinant hCD28-mFc (R3031) and the hCD28 mRNA-LNP complex were used as immunogens to induce the production of anti-human CD28 antibodies. After immunization, peripheral blood was collected from the animals, and PBMCs were isolated to construct a mammalian cell display library (the candidate molecule was the hIgG1 subtype, which can be simultaneously displayed on the cell surface and secreted into the culture medium). Target clones were sorted using the antigen hCD28-mFc (R3031), and the monoclonal supernatant was screened. Monoclonal clones with ideal binding activity to 293T-hCD28 cells and primary T cell activation activity were selected for sequencing. Further amplification culture was conducted for antibody production and purification, yielding CD28 candidate nanobodies: FR2-19 (amino acid sequence of the heavy chain variable region as shown in SEQ ID NO:1), FR2-96 (amino acid sequence of the heavy chain variable region as shown in SEQ ID NO:2), and S3-20 (amino acid sequence of the heavy chain variable region as shown in SEQ ID NO:2). S3-62 (amino acid sequence of the heavy chain variable region as shown in SEQ ID NO:4) and S3-44 (amino acid sequence of the heavy chain variable region as shown in SEQ ID NO:5).

[0177] Example 3: Detection of the binding activity of CD28 candidate nanobodies FACS combined with experimental methods: 293T-hCD28 cells (catalog number: KC-0211) were collected and counted, centrifuged at 300×g for 5 min, resuspended in FCM buffer (3% BSA + 1×PBS), and the cell density was adjusted to 4×10⁻⁶. 6 Cells / mL; the sample was serially diluted 4-fold with buffer; cells were added to 96-well V-plates, followed by one sample (each CD28 candidate nanobody obtained in Example 2 or each control antibody in Example 1), with 50 μL of sample and cells added per well, and incubated at 4°C in the dark for 30 min; centrifuged at 300 ×g for 5 min, discarded the supernatant, washed once with 200 μL of FCM buffer, centrifuged at 300 ×g for 5 min, and discarded the supernatant; secondary antibody (APC-anti-human IgG Fc, 1:500 dilution) was added to 96-well V-plates (100 μL per well), and incubated at 4°C in the dark for 30 min; centrifuged at 300 ×g for 5 min, discarded the supernatant, washed once with 200 μL of FCM buffer, centrifuged at 300 ×g for 5 min, and discarded the supernatant; resuspended in 100 μL of 1×PBS, and analyzed.

[0178] The results showed that the CD28 candidate nanobody exhibited stronger binding activity to 293-hCD28 cells than the positive control R3035 and the positive nanobody control R3796. (See details...) Figure 1 .

[0179] Example 4: Evaluation of primary T cell activation activity of CD28 candidate nanobodies (including CD3 antibody) Collect CHO-hCD32b and CD3 + T cells were centrifuged at 300×g for 5 min, the supernatant was removed, and the cells were counted. The cells were resuspended in experimental medium of 1640+10% FBS, and the cell density was adjusted to 4×10⁶ for CHO-hCD32b cells. 5 cells / ml, CD3 + T cells were 2 × 10 6 50 μL of each of the following 96-well U-plates was added at a concentration of 1 / mL (E:T = 5:1). The diluted OKT3 antibody (commercially available anti-human CD3 antibody) and the test antibody (each CD28 candidate nanobody obtained in Example 2 or each control antibody from Example 1) were added to each well of the 96-well U-plate, mixed well, and incubated at 37°C for 48 hours. After incubation, the 96-well U-plates were centrifuged at 300×g for 5 min, and 120 μL of supernatant was collected from each well. The IFN γ concentration was then detected using a Human IFN gamma Kit.

[0180] The results showed that R3035 is a CD28 superagonist, and the activity of the CD28 candidate nanobody is between that of the strong agonist R3035 and the positive nanobody R3796. (See details...) Figure 2 .

[0181] Example 5: Evaluation of primary T cell activation activity of CD28 candidate nanobodies (without CD3 antibody) Collect CHO-hCD32b and CD3 + T cells were centrifuged at 300×g for 5 min, the supernatant was removed, and the cells were counted. The cells were resuspended in experimental medium of 1640+10% FBS, and the cell density was adjusted to 4×10⁶ for CHO-hCD32b cells. 5 CD3+ T cells / mL: 2 × 10⁶ 6 50 μL of each of the following 96-well U-plates was added at a concentration of 1 / mL (E:T = 5:1). The diluted test antibody (each CD28 candidate nanobody obtained in Example 2 or each control antibody from Example 1) was added to each well of the 96-well U-plate, mixed well, and incubated at 37°C for 48 hours. After incubation, the 96-well U-plates were centrifuged at 300×g for 5 min, and 120 μL of supernatant was collected from each well. The IFN γ concentration was then detected using a Human IFN gamma Kit. The results showed that R3035 is a CD28 superagonist that significantly activates T cells even in the absence of CD3 antibody (OKT3), while all CD28 candidate nanobodies failed to activate T cells in the absence of OKT3. (See details...) Figure 3 .

[0182] The results of Examples 4 and 5 show that the CD28 candidate nanobody of this application has a dependence on the first signal provided by the CD3 antibody, which is an ideal characteristic of the candidate molecule. Example 6: Evaluation of the competitive activity of CD28 candidate nanobody epitopes Collect 293T-hCD28 cells, centrifuge at 300×g for 5 min, remove supernatant, resuspend in FCM buffer (3% BSA + 1×PBS) for counting, and adjust cell density to 2×10⁻⁶. 6The concentration of antibodies was 100 μl / mL, and added to each well of a 96-well V plate. The test antibodies (the CD28 candidate nanobodies obtained in Example 2 and R0861 from Example 1) were used as the first antibody, and the biotin-labeled test antibodies (the CD28 candidate nanobodies obtained in Example 2 and R0861 from Example 1) were used as the second antibody. First, 50 μl of the diluted first antibody was added to each well of the 96-well V plate, mixed, and incubated at 4°C in the dark for 30 min. After incubation, 50 μl of the diluted second antibody was added to each well, mixed, and incubated at 4°C in the dark for 30 min. After incubation, centrifuge the 96-well V-plate at 300×g for 5 min and discard the supernatant. Add 100 μl of secondary antibody (PE-SA, 1:500 dilution) to each well of the 96-well V-plate and incubate at 4°C in the dark for 30 min. Centrifuge at 300×g for 5 min and discard the supernatant. Wash once with 200 μL of FCMbuffer and centrifuge at 300×g for 5 min, then discard the supernatant. Resuspend the plate in 100 μL of 1×PBS and perform analysis.

[0183] The results showed that S3-44 did not compete for epitopes with other antibodies, while all other antibodies did. (See details...) Figure 4 .

[0184] Based on the comprehensive antibody activity data and sequence diversity, S3-44, FR2-19, and S3-62 were selected for humanization.

[0185] Example 7: Humanization of CD28 candidate nanobodies Humanized antibodies can significantly reduce the immune side effects caused by heterologous antibodies in the human body. In this application, the CD28 candidate nanobodies obtained in Example 2 were humanized. The molecules derived from S3-44 after humanization are designated as R4697 (amino acid sequence of the heavy chain variable region as shown in SEQ ID NO:8), R4698 (amino acid sequence of the heavy chain variable region as shown in SEQ ID NO:14), and R4699 (amino acid sequence of the heavy chain variable region as shown in SEQ ID NO:15). The molecules derived from S3-62 after humanization are designated as R4585 (amino acid sequence of the heavy chain variable region as shown in SEQ ID NO:10), R4586 (amino acid sequence of the heavy chain variable region as shown in SEQ ID NO:11), R4587 (amino acid sequence of the heavy chain variable region as shown in SEQ ID NO:12), R4588 (amino acid sequence of the heavy chain variable region as shown in SEQ ID NO:13), and R4589 (amino acid sequence of the heavy chain variable region as shown in SEQ ID NO:7). The molecules derived from FR2-19 after humanization are designated as R4570 (amino acid sequence of the heavy chain variable region as shown in SEQ ID NO:8). The modified molecules (R4697, R4698, R4699, R4585, R4586, R4587, R4588, R4589, R4570, and R4572) were successfully prepared after in vitro recombination, expression, and purification.

[0186] Example 8: Detection of binding activity of CD28 candidate-derived nanobodies FACS combined with experimental methods: 293T-hCD28 cells were collected and counted, centrifuged at 300×g for 5 min, resuspended in FCM buffer (3% BSA + 1×PBS), and the cell density was adjusted to 4×10⁻⁶. 6Cells / mL; The samples (each humanized nanobody obtained in Example 7, R0861 in Example 1, and the parent antibodies S3-44, S3-62, and FR2-19 prepared in Example 2) were serially diluted 4-fold using buffer; Samples and cells were added to 96-well V-plates (50 μL / well for each sample and cell) and incubated at 4°C in the dark for 30 min; Washing: Centrifuge (300 × g / 5 min), discard supernatant, add 200 μL FCM buffer and wash once, centrifuge (300 × g / 5 min), discard supernatant; Add secondary antibody (APC-anti-human IgG Fc, 1:500 dilution) to 96-well V-plates (100 μL / well), incubate at 4°C in the dark for 30 min; Washing: Centrifuge (300 × g / 5 min), discard supernatant, add 200 μL FCM buffer and wash once, centrifuge (300 × g / 5 min), discard supernatant; Loading: Add 100 μL Resuspend in 1×PBS and perform detection.

[0187] The results showed that the binding activity of the aforementioned humanized nanobody on 293-hCD28 cells was comparable to that of its corresponding parent, as shown in Figure 5.

[0188] Example 9: Evaluation of primary T cell activation activity of CD28 candidate-derived nanobodies Collect CHO-hCD32b and CD3+ T cells, centrifuge at 300g for 5 min, remove supernatant, and count. Resuspend cells in 1640 + 10% FBS experimental medium and adjust cell density to 4 × 10⁶ CHO-hCD32b cells. 5 CD3+ T cells / mL: 2 × 10⁶ 6 50 μL / mL (E:T = 5:1) of the antibody was added to each well of a 96-well U-plate. Diluted OKT3 antibody (commercially available anti-human CD3 antibody) and test antibodies (the humanized nanobodies obtained in Example 7, R0861 and R3796 from Example 1) were added to each well of the 96-well U-plate, mixed, and incubated at 37°C for 48 hours. After incubation, the 96-well U-plate was centrifuged at 300×g for 5 min, and 120 μL of supernatant was collected from each well. The IFN γ concentration was detected using a Human IFN gamma Kit.

[0189] The results showed that R3796 was a positive nanobody, and the activity of the candidate derived nanobodies was superior to that of R3796, as shown in Figure 6.

[0190] Example 10: PTM modification of the CDR region of CD28 candidate-derived nanobody The CDR regions of CD28 candidate-derived nanobodies R4572 and R4589 obtained in Example 7 were modified using a polymer-modified (PTM) process. Molecules modified from R4572 were designated R4977 (amino acid sequence of the heavy chain variable region as shown in SEQ ID NO: 150) and R4978 (amino acid sequence of the heavy chain variable region as shown in SEQ ID NO: 151), and molecules modified from R4589 were designated R4979 (amino acid sequence of the heavy chain variable region as shown in SEQ ID NO: 152) and R4980 (amino acid sequence of the heavy chain variable region as shown in SEQ ID NO: 153). The modified molecules were then subjected to in vitro recombination, expression, and purification. The results showed that the PTM-modified antibodies (R4977, R4978, R4979, and R4980) were all successfully prepared.

[0191] Example 11: Detection of binding activity of CD28 candidate-derived nanobodies (after PTM modification) FACS combined with experimental methods: 293T-hCD28 cells were collected and counted, centrifuged at 300×g for 5 min, resuspended in FCM buffer (3% BSA + 1×PBS), and the cell density was adjusted to 4×10⁻⁶. 6 Cells / mL; samples (PTM modified antibody obtained in Example 10, R0861 in Example 1, and parental antibodies R4572 and R4589 prepared in Example 7) were serially diluted 4-fold using buffer; samples and cells were added to 96-well V-plates (50 μL of samples and cells per well) and incubated at 4°C in the dark for 30 min; washing: centrifuge (300 × g / 5 min), discard supernatant, add 200 μL FCM buffer and wash once, centrifuge (300 × g / 5 min), discard supernatant; add secondary antibody (APC-anti-human IgG Fc, 1:500 dilution) to 96-well V-plates (100 μL per well), and incubate at 4°C in the dark for 30 min; washing: centrifuge (300 × g / 5 min), discard supernatant, add 200 μL FCM buffer and wash once, centrifuge (300 × g / 5 min), discard supernatant; instrumentation: resuspend in 100 μL 1×PBS and perform instrumentation.

[0192] The results showed that the binding activity of the aforementioned PTM-modified antibody on 293-hCD28 cells was comparable to that of its corresponding parent antibody. (See details...) Figure 7 .

[0193] Example 12: Evaluation of primary T cell activation activity of CD28 candidate-derived nanobodies (PTM modified) Collect CHO-hCD32b and CD3+ T cells, centrifuge at 300g for 5 min, remove supernatant, and count. Resuspend cells in 1640 + 10% FBS experimental medium and adjust cell density to 4 × 10⁶ CHO-hCD32b cells. 5 CD3+ T cells / mL: 2 × 10⁶ 6 50 μL / mL (E:T = 5:1) of the target antibody was added to each well of a 96-well U-plate. Diluted OKT3 antibody (commercially available anti-human CD3 antibody) and test antibody (the humanized nanobodies obtained in Examples 7 and 10, and R0861 in Example 1) were added to each well of the 96-well U-plate, mixed, and incubated at 37°C for 48 hours. After incubation, the 96-well U-plate was centrifuged at 300×g for 5 min, and 120 μL of supernatant was collected from each well. The IFN γ concentration was detected using a Human IFN gamma Kit.

[0194] The results showed that the primary T cell activation activity of the PTM-modified nanobodies was comparable to that of the parent nanobody. (See details...) Figure 8 .

[0195] In the description of this specification, the references to terms such as "one embodiment," "some embodiments," "example," "specific example," or "some examples," etc., indicate that a specific feature, structure, material, or characteristic described in connection with that embodiment or example is included in at least one embodiment or example of this application. In this specification, the illustrative expressions of the above terms do not necessarily refer to the same embodiment or example. Furthermore, the specific features, structures, materials, or characteristics described may be combined in any suitable manner in one or more embodiments or examples. Moreover, without contradiction, those skilled in the art can combine and integrate the different embodiments or examples described in this specification, as well as the features of different embodiments or examples.

[0196] Although embodiments of this application have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting this application. Those skilled in the art can make changes, modifications, substitutions and variations to the above embodiments within the scope of this application.

Claims

1. An antibody or its antigen-binding fragment, characterized in that, Includes the heavy chain variable region; The heavy chain variable region has an amino acid sequence with at least 80%, 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99%, or 100% identity as shown in any one of SEQ ID NO:1~15 or SEQ ID NO:150~153.

2. An antibody or its antigen-binding fragment, characterized in that, Including HCDRs; The HCDRs are those that are consistent with the HCDRs of the heavy chain variable region defined by the antibodies or their antigen-binding fragments described in SEQ ID NO:1~15 and SEQ ID NO:150~153; Optionally, the HCDRs are defined by the Kabat, Chothia, AbM, Contact, or IMGT system.

3. An antibody or its antigen-binding fragment, characterized in that, Including HCDR1, HCDR2, and HCDR3; among which: HCDR1: NYVMG; HCDR2: TITWX 46 X 47 GTYYADSVKG, X 46 is N or Q, X 47 is G or A; HCDR3: SPLISMDASDFNS; or HCDR1: X1X2AYTMX3, where X1 is empty or L, X2 is empty or F, and X3 is A or G; HCDR2:SLWWNX 48 X 49 ATYYADSVKG, X 48 For D or E, X 49 It can be G or A; HCDR3: KAGX4YX5YNRAEAX6X 45 S, X4 is S, Y, or W, X5 is D or N, X6 is F or Y, X 45 For T or R; or HCDR1: VAGX7D, where X7 is C or S; HCDR2: RVMPDX8VRTYAESVKG, where X8 is G or A; HCDR3: HFWARDY.

4. The antibody or its antigen-binding fragment according to claim 2 or 3, characterized in that, The antibody or its antigen-binding fragment is HCDR1, HCDR2, or HCDR3 as shown in the table below: Optionally, it may further include at least one of HFR1, HFR2, HFR3, and HFR4; Wherein, at least a portion of at least one of HFR1, HFR2, HFR3 and HFR4 is derived from at least one of alpaca-derived antibodies, mouse-derived antibodies, primate-derived antibodies, bovine-derived antibodies, equine-derived antibodies, dairy bovine-derived antibodies, porcine-derived antibodies, sheep-derived antibodies, goat-derived antibodies, canine-derived antibodies, feline-derived antibodies, rabbit-derived antibodies, donkey-derived antibodies, deer-derived antibodies, mink-derived antibodies, chicken-derived antibodies, duck-derived antibodies, goose-derived antibodies or mutants thereof, preferably derived from alpaca-derived antibodies or human antibodies; Optionally, HFR1, HFR2, HFR3, and HFR4 are selected from any one of the following groups: 1) HFR1 has an amino acid sequence as shown in DVQLQESGGGLVQAGGSLRLSCATSGRTFV or an amino acid sequence with at least 90% homology to it. HFR2 has an amino acid sequence as shown in WFRQAPGKEREFVA or an amino acid sequence that is at least 85% homologous to it. HFR3 has an amino acid sequence as shown in RFTISDDRPKNTVYLQMNSLKPEDTGVYYCAA or an amino acid sequence with at least 85% homology to it. HFR4 has an amino acid sequence as shown in WGQGTQVTVSS or an amino acid sequence that is at least 90% homologous to it. Optionally, HFR1: DVQLX9ESGGGX 10 VQX 11 GGSLRLSCATSGRTFV, X9 is Q or V, X 10 For L or V, X 11 It can be A or P; HFR2: WFRQAPGKX 12 X 13 EFVA, X 12 For E or G, X 13 For L or R; HFR3: RFTISDDRX 14 KNTVYLQMNSLX 15 X 16 EDTX 17 VYYCAA, X 14 For P or S, X 15 For K or R, X 16 For P or A, X 17 It can be G or A; HFR4: WGQGTX 18 VTVSS, X 18 For Q or T; Optionally, HFR1: QVQLVESGGGVVQPGGSLRLSCATSGRTFV, HFR2: WFRQAPGKEREFVA, HFR3: RFTISDDRSKNTVYLQMNSLRAEDTAVYYCAA, HFR4: WGQGTLVTVSS; or HFR1: QVQLVESGGGVVQPGGSLRLSCATSGRTFV, HFR2: WFRQAPGKGLEFVA, HFR3: RFTISDDRSKNTVYLQMNSLRAEDTAVYYCAA, HFR4: WGQGTLVTVSS; 2) HFR1: DVQLQESGGGLVQAGGSLRLLCAASGSTFF, HFR2: WFRQAPGKEREFVA, HFR3: RFTVSRDNAENTVFLQMNSLKAEDTAVYYCGA, HFR4: WGRGTQVTVS; 3) HFR1: DVQLVESGGGLVQAGDSLRLSCAASGGTLF, HFR2: WFRQAPGKEREFVG HFR3: RFTISRGNAENTVFLQMNSLKAEDTAVYYCAA, HFR4: WGQGTQVTVS; 4) HFR1 has an amino acid sequence as shown in DVQLQESGGGLVQAGGSLRLLCAASISGRT or an amino acid sequence with at least 85% homology to it. HFR2 has an amino acid sequence as shown in WFRQAPGKEREFVA or an amino acid sequence that is at least 85% homologous to it. HFR3 has an amino acid sequence as shown in RFTISRDNAENTVFLEMNNLKAEDTAVYYCAA or an amino acid sequence with at least 75% homology to it. HFR4 has an amino acid sequence as shown in WGQGTQVT or an amino acid sequence that is at least 60% homologous to it. Optionally, HFR1: DVQLX 19 ESGGGX 20 VQX 21 GGSLRLX 22 CAASISGRT, X 19 For Q or V, X 20 For L or V, X 21 For A or P, X 22 For L or S; HFR2: WFRQAPGKX 23 X 24 EFVA, X 23 For E or G, X 24 For R or L; HFR3: RFTISRDNX 25 X 26 NTX 27 X 28 LX 29 MNX 30 LX 31 AEDTAVYYCAA, X 25 For A or S, X 26 For E or K, X 27 For V or L, X 28 For F or Y, X 29 For E or Q, X 30 For N or S, X 31 For K or R; HFR4: WGQGTX 32 VTX 33 X 34 X 35 X 32 For Q or L, X 33 Empty or V, X 34 Empty or S, X 35 Empty or S; Optionally, HFR1: QVQLVESGGGVVQPGGSLRLSCAASISGRT, HFR2: WFRQAPGKGLEFVA, HFR3: RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAA, HFR4: WGQGTLVTVSS; or OR OR OR HFR1: QVQLVESGGGVVQPGGSLRLSCAASISGRT, HFR2: WFRQAPGKEREFVA, HFR3: RFTISRDNSKNTVYLEMNSLRAEDTAVYYCAA, HFR4: WGQGTLVTVSS; 5) HFR1 has an amino acid sequence as shown in QVQLVESGGGLVQPGGSLRLSCAASGSIFS or an amino acid sequence with at least 95% homology to it. HFR2 has an amino acid sequence as shown in WYREAPGKQRDWVA or an amino acid sequence that is at least 90% homologous to it. HFR3 has an amino acid sequence as shown in RFTISTDNTFSTVYLEMNSLKPEDTAHYYCKT or an amino acid sequence with at least 85% homology to it. HFR4 has an amino acid sequence as shown in WGQGTQVTVLR or an amino acid sequence that is at least 70% homologous to it. Optionally, HFR1: QVQLVESGGGX 36 VQPGGSLRLSCAASGSIFS, X 36 For L or V; HFR2: WYREAPGKQRX 37 WVA, X 37 For D or R; HFR3:RFTISTDNX 38 FSTVYLEMNSLX 39 X 40 EDTAX 41 YYCKT, X 38 For T or S, X 39 For K or R, X 40 For P or A, X 41 For H or V; HFR4: WGQGTX 42 VTVX 43 X 44 X 42 For Q or L, X 43 For L or S, X 44 For R or S; Optionally, HFR1: QVQLVESGGGVVQPGGSLRLSCAASGSIFS, HFR2: WYREAPGKQREWVA, HFR3: RFTISTDNSFSTVYLEMNSLRAEDTAVYYCKT, HFR4: WGQGTLVTVSS; or HFR1: QVQLVESGGGVVQPGGSLRLSCAASGSIFS, HFR2: WYREAPGKQREWVA, HFR3: RFTISTDNSFSTVYLEMNSLKAEDTAVYYCKT, HFR4: WGQGTLVTVSS; or HFR1: QVQLVESGGGVVQPGGSLRLSCAASGSIFS, HFR2: WYREAPGKQREWVA, HFR3: RFTISTDNSFSTVYLEMNSLKAEDTAHYYCKT, HFR4: WGQGTLVTVSS.

5. The antibody or its antigen-binding fragment according to claim 2 or 3, characterized in that, The antibody or its antigen-binding fragment has a heavy chain variable region as shown in any one of the amino acid sequences of SEQ ID NO: 1-5, 8, 14-15, or a heavy chain variable region shown in an amino acid sequence having at least 85% homology with it. Optionally, the antibody or its antigen-binding fragment has a heavy chain variable region as shown in any one of the amino acid sequences of SEQ ID NO:2-3; and / or The antibody or its antigen-binding fragment has a heavy chain variable region as shown in the amino acid sequence of SEQ ID NO: 1 or a heavy chain variable region shown in an amino acid sequence having at least 90% homology with it; and / or The antibody or its antigen-binding fragment has a heavy chain variable region as shown in the amino acid sequence of SEQ ID NO:4 or a heavy chain variable region having at least 85% homology with it; and / or The antibody or its antigen-binding fragment has a heavy chain variable region as shown in the amino acid sequence of SEQ ID NO:5 or a heavy chain variable region having at least 90% homology with it; and / or The antibody or its antigen-binding fragment has a heavy chain variable region as shown in any one of the amino acid sequences of SEQ ID NO:8, 14-15, or a heavy chain variable region shown in an amino acid sequence having at least 90% homology with it. Optionally, the antibody or its antigen-binding fragment has a heavy chain variable region as shown in any one of the amino acid sequences of SEQ ID NO:6-15.

6. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, characterized in that, The antibody or its antigen-binding fragment further includes CH2 and CH3 of the heavy chain constant region; Optionally, at least a portion of the heavy chain constant region is derived from at least one of alpaca-derived antibodies, mouse-derived antibodies, primate-derived antibodies, bovine-derived antibodies, equine-derived antibodies, dairy bovine-derived antibodies, porcine-derived antibodies, sheep-derived antibodies, goat-derived antibodies, canine-derived antibodies, feline-derived antibodies, rabbit-derived antibodies, donkey-derived antibodies, deer-derived antibodies, mink-derived antibodies, chicken-derived antibodies, duck-derived antibodies, goose-derived antibodies, or mutants thereof, preferably from alpaca-derived antibodies or human antibodies; Optionally, the heavy chain constant region includes a heavy chain constant region selected from IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE or IgD; Optionally, the N end of the heavy chain constant region is connected to the C end of the heavy chain variable region; Optionally, the heavy chain constant region is selected from hIgG1.

7. A biomaterial, characterized in that, The biomaterial includes any one of the following (i) to (vii): (i) A nucleic acid molecule that encodes an antibody or an antigen-binding fragment thereof as described in any one of claims 1 to 6; (ii) A vector comprising the nucleic acid molecule described in (i); (iii) A cell or host comprising: (i) the nucleic acid molecule or (ii) the vector; or expressing the antibody or antigen-binding fragment thereof as described in any one of claims 1 to 6; (iv) A conjugate, characterized in that it comprises: the antibody or antigen-binding fragment thereof as described in any one of claims 1 to 6, and a conjugate portion therewith; Optionally, the coupling portion includes a selection from purification tags or labels; Optionally, the purification label or tag includes at least one selected from colloidal gold, radioactive labeling, luminescent substances, colored substances, enzymes, biotin / avidin, and spin labeling; Optionally, the purification label or marker includes at least one selected from fluorescent markers, chromophore markers, and electron-dense markers; Optionally, the purification label or marker includes one or more selected from radioactive isotopes, fluorophores, rhodamine and its derivatives, luciferase, luciferin, horseradish peroxidase, alkaline phosphatase, β-galactosidase, glucosylamylase, lysozyme, carbohydrate oxidase, glucose oxidase, galactose oxidase and glucose-6-phosphate dehydrogenase. Optionally, the coupling portion includes at least one selected from magnetic microspheres, plastic microspheres, plastic microparticles, microporous plates, glass, capillaries, nylon, and nitrocellulose membranes; (v) A reagent or kit, characterized in that it comprises: the antibody or antigen-binding fragment thereof as described in any one of claims 1 to 6, or the conjugate as described in (iv).

8. A pharmaceutical composition, characterized in that, Includes the antibody or antigen-binding fragment thereof as described in any one of claims 1 to 6, and the biological material as described in claim 7; Optionally, pharmaceutically acceptable excipients may be further included.

9. Use of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 6, the biomaterial according to claim 7, or the pharmaceutical composition according to claim 8 in the preparation of a medicament for the treatment, prevention, or relief of diseases, symptoms, or conditions associated with tumors, inflammation, autoimmune diseases, infections, or immune rejection in organ transplantation.

10. A method for detecting CD28, characterized in that, include: An immune complex is formed by contacting the antibody or its antigen-binding fragment as described in any one of claims 1 to 6 and the biomaterial as described in claim 7 with the sample to be tested. Optionally, based on the signal of the immune complex, it is determined whether the sample to be tested contains CD28 or the amount of CD28. Optionally, the immune complex further includes a second antibody, which binds to the antibody or its antigen-binding fragment; Optionally, the immune complex further includes a second antibody that binds to CD28; Optionally, the signal may include a fluorescence signal.

Citation Information

Patent Citations

  • CD28 single domain antibodies and multivalent and multispecific constructs thereof

    US20230348600A1

  • Trispecific binding proteins, methods, and uses thereof

    WO2020210392A1